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Abstract
Generating antibodies against T-independent and T-dependent antigens requires TollLike receptor (TLR) engagement on B cells for efficient responses. However,
transcriptional regulation of TLR responses in B cells is not well understood.
Transcription factors of the E26 transformation-specific family (ETS) are critically
important for regulating hematopoiesis and cellular function. PU.1, Spi-B, and Spi-C are
highly related ETS transcription factors that can bind nearly identical DNA sequences in
the genome. PU.1 and Spi-B (encoded by Spi1 and Spib respectively) are important for B
cell development and function, but the function of Spi-C (encoded by Spic) in B cells is
not clear. The primary objective of this study was to determine the function of PU.1, SpiB, and Spi-C during B cell development, and during TLR-mediated responses. It was
hypothesized that PU.1 and Spi-B were required for positively regulating components of
TLR responses, and Spi-C inhibited PU.1 and Spi-B targets. Spi1+/-Spib-/- (PUB) B cells
proliferated poorly in response to TLR ligands compared to WT B cells. The NF-κB
family member p50 (encoded by Nfkb1) is required for LPS responsiveness in mice, and
PUB B cells expressed reduced Nfkb1 mRNA transcripts and p50 protein. Forced
expression of p50 in PUB B cells was capable of restoring TLR-mediated proliferation. It
was determined that PU.1 and Spi-B directly regulated the Nfkb1 promoter, and were
required for proper TLR-mediated responses. Next, Spib-/-Spic+/- mice were generated to
determine if Spi-C was functionally redundant with Spi-B. Spib-/-Spic+/- mice had restored
number of B cells in the spleen, and had restored proliferative responses compared to
Spib-/- mice. Steady-state Nfkb1 levels were elevated in Spib-/-Spic+/- B cells compared to
Spib-/- B cells, and was the potential mechanism of the Spib-/-Spic+/- phenotype. It was
demonstrated that Spi-B directly activated the Nfkb1 gene, while Spi-C directly repressed
this gene. These results suggest that PU.1 and Spi-B are required for transcriptional
activation of Nfkb1, and Spi-C has a negative regulatory role in B cell development and
function. Determining the transcriptional regulation of B cell responses has important
implications for understanding antibody forming responses, such as those seen in
vaccinations.
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Chapter 1

1

Introduction
Humans are exposed to millions of potential pathogens on a daily basis.

Therefore, protection from nearly unlimited pathogens is required over a lifetime. The
ability of humans to avoid infection upon repeated exposure to pathogens is dependent on
cellular components of the innate and adaptive immune system. Vaccines have eliminated
many of the world’s worst diseases such polio and smallpox, but there are currently no
vaccines for many serious diseases such as HIV, cancers, and malaria. Generating
vaccine-mediated protection in humans is complex; most current available vaccines have
been developed with limited understanding of how they activate the immune system
(Siegrist, 2008). Most effective vaccinations are mediated by antibodies produced by B
cells. Antibodies function to activate complement, and neutralize or opsonize toxins and
pathogenic microorganisms to aid in their destruction (Pone et al, 2010). Aside from the
economic and commercial priorities of the vaccine development industry, the difficulty in
generating protective vaccines is in maintaining long-lasting protection through the
correct presentation of antigens (Plotkin, 2009). Therefore, understanding the regulation
of B cell development, maintenance, and responses to antigens is important for
determining the cellular mechanism of a vaccine.

1.1 B cell origin, function, and subsets
B cells are an essential component of the immune system. They can function as
professional antigen presenting cells, modulate immune responses by cytokine
production, and are the sole producers of antibodies (Pone et al, 2010). Each B cell
produces a single unique antibody specificity, which is generated from germline
recombination of the immunoglobulin (Ig) genes. Identical copies of unique Igs are
embedded on the surface of a B cell, termed the B cell receptor (BCR), which
distinguishes B cells from other lymphocytes. The BCR can be further diversified by Ig
class switch recombination (CSR) and somatic hypermutation events. B cells initially
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express and produce IgM and IgD isotypes, but can express IgG, IgA, or IgE following
CSR. BCRs form clusters when bound by an antigen, thereby bringing together signaling
molecules to contribute to B cell differentiation (Pone et al, 2010). In both mice and
humans, B cells develop in the bone marrow (BM), and then migrate to the spleen to
mature.

1.1.1 B cell development in the bone marrow
B cell development is a well-studied system in mice, and unlike many other
somatic tissues, its development continues even in adults. There are many stages of B cell
development, initiating with a pluripotent hematopoietic stem cell (HSC). HSCs
differentiate into various progenitor stages, going in the order of a multipotent progenitor
(MPP), lymphoid-primed multipotent progenitor (LMPP), and common lymphoid
progenitor (CLP) (Nagasawa, 2006). Each progenitor stage is capable of generating a
specific cell lineage or progressing to the next stage. CLPs can differentiate into T cells,
dendritic cells, NK cells, and B cells. In 1991, Hardy et al defined a number of progenitor
B cell stages in the bone marrow of mice, termed fractions A, B, C, D, E, and F (Hardy et
al, 1991). The fractions progress in alphabetical order and are characterized based on
cell-surface phenotype, differences in functionality, and Ig-gene rearrangement (Hardy et
al, 1991) (Figure 1.1). B cells undergo Ig-gene rearrangement during differentiation,
which is an important process for generating a repertoire of Ig receptors capable of
recognizing any antigen.
Fraction A cells (B220+CD43+CD24-BP-1-IgM-) are a heterogeneous population
containing pre-pro B cells, which are the earliest population committed to the B cell
lineage and require stromal contact for growth (Hardy et al, 1991; Li et al, 1996).
Fraction A cells differentiate into fraction B (B220+CD43+CD24+BP-1-IgM-) (pro B)
cells, where rearrangement of the DJ (diversity and junction) regions of the Ig heavy
chain begins. In addition, fraction B cells are less dependent on stromal cell contact for
growth, but require IL-7 for growth (Hardy et al, 1991; Li et al, 1996). At the fraction C
(B220+CD43+CD24+BP-1+IgM-) (late-pro B cell) stage, most cells have variable (V)DJ
Ig heavy chain rearrangements, and a small percentage of DJ rearranged Ig light chain
can be detected (Ehlich et al, 1993). Rearranged heavy chain expression leads to surface
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expression of the pre-BCR complex, which provides signaling for further differentiation.
Within the fraction C population, a subpopulation of cells express higher levels of CD24
and are termed fraction C’ (large-pre B) cells. Fraction C cells differentiate into fraction
C’ cells once receiving a signal through the pre-BCR, allowing the cells to enter cell
cycle (Hardy et al, 1991). IL-7 is also required for growth at the fraction C cell stage, but
stromal contact is not required (Hardy et al, 1991). B cell development proceeds to
fraction D (B220+CD43-CD24+BP-1+IgM-), consisting of small pre-B cells. A large
portion of fraction D cells will have VJ rearrangement of the Ig light chain occur at this
stage (Hardy et al, 1991). Cells become fraction E once the Ig light chain has fully
rearranged VJ regions, and cells begin to express IgM. Fraction E cells are considered
immature B cells, which migrate to the spleen to differentiate into mature B cells. Mature
B cells capable of recirculation can be found in the bone marrow and are classified as
fraction F cells, which express IgD, IgM, and higher levels of B220 compared to fraction
E cells.
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Figure 1.1. Defining Hardy Fractions of B cell development in the bone marrow.
Hardy fractions of B cell development are shown. Differences in cell surface molecules,
immunoglobulin rearrangement, and growth dependence are indicated. Line presence and
thickness represents the level of cell surface molecule expression or the dependence of
growth conditions for the various stages of development. Figure is adapted from Hardy et
al. (Hardy et al, 1991).
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1.1.2 Immature B cells
Transitional B cells are an important link between the BM and periphery during B
cell development. Immature B cells express BCR on the cell surface, and B cells
recognizing self-antigens will undergo deletion, receptor editing, or anergy (Chung et al,
2003). Non-self-reactive, immature B cells leave the bone marrow and progress through
transient transitional (T1 and T2) B cell stages. Transitional B cells in the spleen are
identified by CD93 (AA4.1) expression, a marker of immaturity. In addition to CD93, T1
and T2 B cells are characterized by the surface markers IgMhiIgD-CD21-CD23- and
IgMhiIgD+CD21+CD23+ respectively (Chung et al, 2003). T1 B cells do not have the
ability to recirculate and are found in the bone marrow or spleen. T2 B cells, which
develop from T1 B cells, enter the splenic follicles and have the ability to recirculate
(Pillai & Cariappa, 2009). The differentiation from T1 to T2 B cells requires basal BCR
signals, BAFF survival signals, and non-canonical NF-κB signals (Pillai & Cariappa,
2009). At the T2 B cell stage, cells then develop into mature B cells. The BM of a normal
6-8 week-old mouse will have ~2x107 immature B cells generated daily, but only ~10%
will actually reach the periphery (Rolink et al, 1998).

1.1.3 Mature B cells
Mature B cells can recirculate through secondary lymphoid organs or join
enriched static components in the spleen, peritoneal, and pleural cavities (Martin &
Kearney, 2000). The spleen is the largest secondary lymphoid organ and contains about
one-fourth of the body’s lymphocytes (Cesta, 2006). Various B cell subsets can be found
in the spleen including B-1, B-2, and B regulatory cells (Table 1.1).

1.1.3.1

B regulatory cells

The smallest populations of B cells in the spleen are B regulatory cells (Bregs),
which consists of approximately 1-2% of the total B cells in the spleen, and have a
unique phenotype of CD19hiCD1dhiCD5+ (Yanaba et al, 2008). Bregs are also known as
B10 cells since they produce the highest levels of interleukin-10 (IL-10) of all B cell
subsets (Yanaba et al, 2008). IL-10 has anti-inflammatory and suppressive effects on
most hematopoietic cells (Bouaziz et al, 2012), thus Bregs are capable of suppressing T
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cell-mediated inflammation in vivo (Yanaba et al, 2008). Although the current
developmental origin of Bregs is unknown, it is hypothesized that they are differentiated
from either T2 marginal zone precursor (MZP) B cells or a separate Breg progenitor
population (Vitale et al, 2010).

1.1.3.2

B-1 cells

B cells in the pleural and peritoneal cavities of adults are primarily B-1 cells, but
they can also be found in the spleen in low frequencies (Baumgarth, 2011). B-1 cells are
defined as CD19hiCD43+CD23-IgMhiIgDlow. They can be further subdivided into B-1a or
B-1b cells according to the presence or absence of CD5 respectively (Baumgarth, 2011).
B-1 cells generate natural IgM and IgA antibodies, which recognize self-antigens and
pathogen-expressed molecules without prior antigen exposure (Racine & Winslow,
2009). Recent studies have also demonstrated that B-1 cells from the liver and peritoneal
cavity have phagocytic capabilities (Nakashima et al, 2012; Parra et al, 2012), which
suggests a previously unacknowledged mechanism of pathogen clearance by B cells.
There has been controversy regarding the development of B-1 cells in relation to B-2
cells. However, there is increasing evidence suggesting that B-1 cells develop from a
separate lineage from B-2 cell progenitors (Montecino-Rodriguez & Dorshkind, 2012).
B-1 progenitor cells have been reported to arise as early as day 9 of gestation in the yolk
sac of mice (Yoshimoto et al, 2011), but then develop from HSCs during later times
(Montecino-Rodriguez & Dorshkind, 2012). Fetal liver and neonatal bone marrow HSCs
are able of differentiating into B-1 or B-2 cells (Kikuchi & Kondo, 2006), but
commitment to either lineage is already determined by the CLP stage of development
(Barber et al, 2011).

1.1.3.3

B-2 cells: marginal zone and follicular B cells

The spleen is comprised of primarily B-2 cells called marginal zone (MZ) and
follicular (FO) B cells. MZ B cells account for approximately 15% of the total B cells in
the spleen, and FO B cells make up more than 70% (Baumgarth, 2011). Both MZ and FO
B cells express high levels of B220 and CD19, and no longer express CD93. MZ B cells
are characterized by high levels of surface receptors IgM, CD21, and CD1d, and low
levels of IgD and CD23 (Pillai et al, 2005). Follicular B cells express lower levels of
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IgM, CD21, and CD1d, and high levels of IgD and CD23 (Pillai et al, 2005). Aside from
having different surface phenotypes, MZ and FO B cells also have different functions.
There are differences in activation between MZ and FO B cells. Activation of B cells
occurs either through a T-cell independent (TI) or T-cell dependent (TD) manner. TI
responses occur in the absence of T cell help, and can be further subdivided into TI-type I
(TI-I) or TI-type 2 (TI-II). MZ B cells reside between the marginal sinus and the red pulp.
This is an ideal location to meet and respond rapidly to blood-borne pathogens, and thus
MZ B cells play an important role in TI immune responses (Pillai & Cariappa, 2009;
Pillai et al, 2005). Examples of TI-I antigens include lipopolysaccharide (LPS), an outer
membrane component found in all Gram-negative bacteria, which binds to Toll-like
receptor (TLR)4. An example of a TI-II antigen is dinitrophenylated ficoll (DNP-ficoll),
which result in B cell activation through BCR engagement and clustering, independent of
T cell help (Obukhanych & Nussenzweig, 2006). In contrast, FO B cells have an
important role in TD immune responses to protein antigens (Pillai & Cariappa, 2009). TD
antigens involve cross-linking BCRs and processing the antigens onto major
histocompatibility complex class II (MHCII) molecules, and then are typically followed
by CD40 co-stimulation by a T-helper cell. FO B cells are not only found in the spleen,
but can also circulate in the blood. FO B cells are therefore better at generating effective
antibody responses after interacting with T cells in response to blood-borne pathogens.
MZ B cells express elevated T cell co-signaling molecules at basal and stimulated levels
compared to FO B cells (Oliver et al, 1999). In addition, MZ B cells are also more readily
activated and proliferative than FO B cells after stimulation with LPS, anti-IgM, or antiCD40, and can become potent antigen presenting cells for T cells (Oliver et al, 1997;
Oliver et al, 1999; Snapper et al, 1993; Snapper et al, 1996b).
A small fraction of MZ or FO B cells which are activated can become plasma
cells or memory B cells. Plasma cells are terminally differentiated B cells committed to
antibody secretion. Plasma cells constitutively secrete antibody against an antigen to
provide protection during a primary response, but are unable to respond to secondary
infections because of diminished surface Ig expression (Manz et al, 1998). In contrast,
memory B cells express BCRs for an eliciting antigen and can rapidly secrete high
amounts of antibody upon secondary exposure. Both memory B cells and plasma cells are
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Table 1.1. Phenotype, frequency, and function of B cell subsets located in mouse spleens
Breg

B-1(a/b)

MZ

FO

B220+

B220+

B220+

B220+

CD19hi

CD19+

CD19+

CD19+

CD5+

CD5(+/-)

CD5-

CD5-

CD1dhi

CD1dhi

CD1dhi

CD1dlow

CD21hi

CD21low

CD23-

CD23low

CD23hi

CD43+

CD43-

CD43-

IgMhi

IgMhi

IgMlow

IgDlow

IgDlow

IgDhi

~1%

~2%

~15%

>70%

Major Function

Anti-

Production of

Rapid response

Humoral

in spleen

inflammatory

natural

to TI antigens

response to TD

roles; production

antibodies

Phenotype

Frequency in
spleen

of IL-10

antigens
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important components for long-lasting antibody-mediated immunity as seen in
vaccinations.

1.2 B cell related diseases
A fine balance between activation and inhibition of immune function is required.
Loss of B cell function can make an individual more susceptible to infection, whereas
gain of function during B cell development or activation can lead to autoimmunity.
Furthermore, there are instances where either a gain of function or loss of function in B
cells can result in a cancerous state.

1.2.1 B cell immunodeficiencies
Diseases related to loss of B cell function are classified into three major
categories of B cell immunodeficiencies: 1) defects in early B cell development, 2) CSR
defects, and 3) common variable immunodeficiency (CVID) (Conley et al, 2009). In all
cases of B cell immunodeficiencies, there is a reduction in antibody production, which
results in increased susceptibility to recurrent infections (Conley et al, 2009). Defects in
early B cell development result in recurrent infections, hypogammaglobulinemia, reduced
B cells in the periphery, and a block in early B cell differentiation (Conley et al, 2009).
The most prevalent form of defects in early B cell development is X-linked
agammagobulinemia (XLA), which accounts for approximately 85% of cases (Conley et
al, 1998). XLA is caused primarily by mutations in the gene Btk, and is characterized by
a marked decrease in mature B cells and lack of antibodies of all isotypes (Vetrie et al,
1993). A smaller proportion of XLA cases have been reported to be caused by mutations
in genes encoding pre-BCR or BCR signaling components, such as Igα, Igβ, λ5, µ heavy
chain, and BLNK (Conley et al, 2009; Minegishi et al, 1999a; Minegishi et al, 1998;
Minegishi et al, 1999b; Yel et al, 1996).
Defects in CSR result in high levels of serum IgM, but little to no production of
IgG, IgA, and IgE antibodies (Conley et al, 2009). CSR defects are primarily caused by
mutations in Cd40lg (Allen et al, 1993). The loss of CD40-CD40L interaction results in
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impaired T cell, B cell, and monocyte function, which can lead to opportunistic infections
(Fuleihan, 1998). Mutations in Aicda, which encodes for activation-induced cytidine
deaminase (AID), have also been attributed with defects in CSR (Revy et al, 2000). AID
initiates CSR and somatic hypermutation during Ig gene rearrangement by deaminating
cytosine residues in Ig heavy chain variable regions and switch regions (Muramatsu et al,
2000; Perlot et al, 2008).
CVID is characterized by reduced serum immunoglobulins and highly variable
clinical features (Cunningham-Rundles & Bodian, 1999). In contrast to other B cell
immunodeficiencies, CVID patients can have normal B cells, but low numbers of
memory B cells (Wehr et al, 2008). The predisposing genetic factors associated with
CVID are unknown, but mutations in the genes encoding ICOS, CD19, and TACI have
been identified to small groups of patients (Grimbacher et al, 2003; van Zelm et al, 2006).

1.2.2 Autoimmunity
Several checkpoints occur during B cell development to ensure that B cells do not
recognize host or self-antigens, collectively called central B cell tolerance. These
mechanisms include BCR editing (Gay et al, 1993; Tiegs et al, 1993), deletion of selfreactive B cells (Nemazee & Buerki, 1989), and anergy (Nossal & Pike, 1980). Failure to
regulate self-tolerance in B cells is associated with autoimmunity. Autoimmunity is
characterized by immune activation in response to self-antigens leading to tissue
destruction and organ failure (Alberghini et al, 2015). Some commonly studied
autoimmune diseases include systemic lupus erythematosus (SLE), rheumatoid arthritis,
multiple sclerosis, and diabetes (Morel, 2004). B cells can contribute to autoimmune
diseases through secretion of autoantibodies, presentation of autoantigens to T cells, and
secretion of proinflammatory cytokines (Chan & Shlomchik, 1998; Harris et al, 2000;
Wong et al, 2004). Therefore, understanding mechanisms of B cells development and
function can provide therapeutic targets for preventing B cells from becoming autoreactive.
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1.2.3 B cell leukemia and lymphoma
If control of activation, proliferation or apoptosis is deregulated in B cells, various
forms of cancers can arise depending on the initiating cell stage (Figure 1.2). Both
leukemias and lymphomas have subtypes involving B cells. Leukemia is a cancer of
bone marrow origin which results in abnormal growth of leukocytes. Lymphomas are
characterized by uncontrolled lymphocyte growth which affects lymph nodes. Mutations
in components of BCR signaling have been attributed to both of these diseases (Buchner
et al, 2015; Burger & Chiorazzi, 2013; Davis et al, 2010). Chronic activation of BCR
signaling can lead to proliferation and the activation of pro-survival genes, preventing
malignant cells from undergoing apoptosis (Davis et al, 2001; Davis et al, 2010; Packham
et al, 2014). As such, therapeutic strategies for treating leukemia and lymphomas have
involved using drugs which inhibit BCR signaling kinases, such as Btk and Syk (Davis et
al, 2010; Woyach et al, 2012). Understanding the regulation of B cell development and
BCR signaling has provided key insights into how to treat some of these diseases.
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Figure 1.2. Examples of B cell associated malignancies which can arise from different B
cell subsets.
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1.3 Toll-Like Receptors
Toll-Like receptors (TLR) are evolutionarily conserved, single-spanning
transmembrane receptors expressed both intracellularly and on the surfaces of many cell
types. TLRs belong to the Interleukin-1 receptor (IL-1R) family, as the receptors contain
a C terminal intracellular Toll/IL-1R (TIR) signaling domain (West et al, 2006). TLRs
function as hetero- or homo-dimers, and recognize conserved structures of viruses,
bacteria, protozoa, and fungi, collectively called pathogen associated molecular patterns
(PAMPs) (West et al, 2006). Recognition of ligands by TLRs is dependent on the Nterminal leucine-rich-repeat (LRR) motif, which contains 24 amino acids forming an αhelix and β-sheet joined by a loop (Kawai & Akira, 2007). Human TLRs contain 19-25
LRRs which together form a horseshoe-shaped structure (Bell et al, 2005). TLRs were
initially identified in Drosophila melanogaster through a cDNA library screen for genes
that regulated embryonic polarity during development (Hashimoto et al, 1988). TLR
homologues in vertebrates, specifically TLR4, were discovered in mice and humans for
being important during LPS-mediated inflammatory responses (Medzhitov et al, 1997;
Poltorak et al, 1998). To date, thirteen members of TLRs have been identified in mice,
and eleven in humans (Kawai & Akira, 2007). Each TLR recognizes one or more distinct
categories of PAMPs.
LPS is the most widely studied ligand for TLR signaling induction. The
mechanism for LPS recognition through TLRs is complex. The serum protein LPSbinding protein (LBP) first binds to LPS and transfers it to the molecule CD14. Delivery
of LPS by CD14 is then transferred to TLR4, which forms a complex with MD-2 (Botos
et al, 2011) . MD-2 is a coreceptor which binds to TLR4 and LPS (Visintin et al, 2006),
and is essential for LPS recognition (Nagai et al, 2002a). Furthermore, immune cells
including B cells, DCs, and macrophages express radioprotective 105 (RP105), an
additional surface molecule which is also capable of LPS recognition (Fugier-Vivier et al,
1997; Miyake et al, 1995). RP105 interacts with the coreceptor MD-1 for LPS
recognition and signaling transduction (Nagai et al, 2002b). Interestingly, the functional
roles of RP105 differ between B cells, DCs, and macrophages. RP105/MD1 enhances
LPS signaling through TLR4 in B cells (Ogata et al, 2000), but it functions as a negative
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regulator in macrophages and DCs by directly inhibiting LPS binding to TLR4
(Divanovic et al, 2005).
B cells express and respond to ligands of TLR1, TLR2, TLR4, TLR6, TLR7/8,
and TLR9 (Dasari et al, 2005; Genestier et al, 2007; Gururajan et al, 2007; Hornung et al,
2002). B cells up-regulate cytokine synthesis, antibody secretion, and cell proliferation
upon binding of TLR ligands onto their receptors, as a result of activation of the
transcription factor nuclear factor (NF)-κB (Bekeredjian-Ding & Jego, 2009). The
signaling events following TLR ligand binding have been well characterized (Figure 1.3).
Activation of TLRs elicits a signaling response through a MyD88-dependent or TIRdomain-containing adapter-inducing interferon-β (TRIF)-dependent pathway (Kawai &
Akira, 2006). Except for TLR3, all TLRs can recruit the MyD88 adaptor protein for TLR
signaling (Kawai & Akira, 2006; Kawai & Akira, 2007). On the other hand, TLR3 and
TLR4 are capable of activating NF-κB through the recruitment of the adapter protein
TRIF (Kawai & Akira, 2006). For the MyD88-dependent pathway, the association of
TLRs and MyD88 stimulates and recruits members of the interleukin-1 receptorassociated kinase (IRAK) family, including IRAK-1, IRAK-2, IRAK-4, and IRAK-M
(Kawai & Akira, 2006; Kawai & Akira, 2007). Once IRAK-4 and IRAK-1 are
phosphorylated, they dissociate from MyD88 and activate tumor necrosis factor receptorassociated factor 6 (TRAF-6) (Kawai & Akira, 2006; Kawai & Akira, 2007). A complex
of proteins is formed with TRAF-6 which in turn activates transforming growth factor-βactivated protein kinase 1 (TAK1). The TAK1 complex activates the IκB kinase (IKK)
complex, consisting of IKKα, IKKβ, and IKKγ (Kawai & Akira, 2006; Kawai & Akira,
2007). The IKK complex phosphorylates IκBs for polyubiquitination and proteasomal
degradation, which results in NF-κB subunits to be released into the nucleus and bind to
DNA targets. Additionally, TLR ligands such as LPS are capable of activating
phosphoinositide 3-kinase (PI3K) within minutes of B cell stimulation (Bone &
Williams, 2001). TLR signaling can activate the PI3K pathway through the B cell adaptor
for PI3K (BCAP). Phosphorylated BCAP accumulates at the cell membrane after LPS
stimulation, and allows its associated PI3K to signal downstream (Ni et al, 2012). It has
been demonstrated that sustained PI3K signaling and antigen receptor engagement by
either LPS or BCR crosslinking is necessary for proliferation and survival of activated B
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cells (Donahue & Fruman, 2003). Furthermore, it has been suggested that promoting
activation of full TLR signaling requires MHCII interaction with Bruton’s tyrosine kinase
(Btk) and CD40 (Liu et al, 2011); therefore, TLR signaling is complex and its
components may have redundant functions.
Understanding TLR activation in B cells has implications for human health and
disease. TLR signaling in B cells is required for T-dependent antibody responses (Pasare
& Medzhitov, 2005). It has been suggested that the production of effective neutralizing
antibody responses, as seen in vaccinations, involves direct TLR ligand binding on B
cells (Kasturi et al, 2011). Moreover, TLRs may have roles in B cell malignancies. One
hypothesis is that chronic infections leading to TLR activation can induce excessive
somatic hypermutation and CSR events, which can transform normal B cells into
malignancies such as B cell lymphoma (Isaza-Correa et al, 2014). TLR stimulation can
also lead to the proliferation of malignant B cells, and induce a cytokine profile which
creates an immunosuppressive microenvironment (Isaza-Correa et al, 2014). Although
much is known about TLRs and B cells, transcriptional regulation of genes involved for
TLR expression on B cells remains unclear.
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Figure 1.3. MyD88-dependent TLR signaling pathway in B cells.
A simplified schematic of the TLR signaling pathway is shown. TLR1/2, TLR 2/6, and
TLR 4 are located at the cell surface, whereas TLR7, TLR8, and TLR9 are located in
endosomes. Ligand binding results in a cascade of signaling events which eventually
leads to polyubuitination of Iκ-Bɑ, which allows NF-κB (p65/p50 heterodimer) to
translocate into the nucleus and upregulate genes involved in survival, proliferation, and
cytokine and antibody secretion.
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1.4 Transcriptional Regulation
Cell fates and cellular function are regulated through complex and precise gene
expression patterns (Spitz & Furlong, 2012). Regulation of gene expression is controlled
by transcription factors, which are proteins that bind to cis-acting regulatory DNA
sequences in order to recruit coactivators and RNA polymerase II (RNA Pol II) to target
genes. RNA pol II is responsible for the transcription of DNA to mRNA in eukaryotes.
Transcription factors are essential for the activation or repression of gene expression. Cisregulatory DNA sequences include core promoters and promoter-proximal elements
located near the transcription start site (TSS), and distal enhancers, silencers, and
insulators (Figure 1.4) (Minegishi et al, 1999b; Spitz & Furlong, 2012). These cisregulatory elements contain DNA sequences which transcription factors recognize and
bind. Transcription factors can bind to promoters within a thousand base pairs of the TSS,
or further away at distal enhancer, silencer, or insulator elements up to 1 million base
pairs from the promoter (Maston et al, 2006). Furthermore, each regulatory element can
contain multiple transcription factor binding sites, which drastically increases the ability
to generate unique expression patterns. Therefore, understanding how gene expression
profiles are regulated by regulatory sequences and transcription factors can give insight to
development and function of cells and tissues.
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Figure 1.4. Examples of cis-regulatory elements found in transcriptional regulation.
A simplified schematic of the transcriptional regulatory elements found in eukaryotes.
Transcription factors can bind to proximal and core promoters, and distal enhancers,
silencers, and insulators to regulate gene transcription. Figure is adapted from Ong and
Corces (Ong & Corces, 2011).
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1.5 Transcription factor NF-κB
The nuclear factor-κB (NF-κB) family of transcription factors was initially
discovered in B cells by its ability to bind an enhancer element within the
immunoglobulin-κ chain (Sen & Baltimore, 1986b). The expression of NF-κB was later
determined to be inducible, and expressed in other lymphoid and non-lymphoid cell types
(Sen & Baltimore, 1986a). NF-κB is present in the cytoplasm of most cells in an inactive
complex with IκB inhibitor proteins (Baeuerle & Baltimore, 1988), which are identified
by repeat 33 amino acid long ankyrin motifs (Li & Verma, 2002). Activation of NF-κB
allows for its translocation into the nucleus, where it can bind to promoters or enhancers
of genes containing the consensus sequence GGGRNYYYCC (R is any purine; Y is any
pyrimidine; N is any nucleotide) to initiate transcription (Chen et al, 1998). The NF-κB
family is composed of five subunits: NF-κB1 (p105/p50) , NF-κB2 (p100/p52), RelA
(p65), RelB, and c-Rel, which all interact with DNA as hetero- or homodimers (Hayden
& Ghosh, 2008). Both p100 and p105 are precursor proteins for p50 and p52
respectively, and contain ankyrin repeats which can function as IκB-like proteins (Li &
Verma, 2002). Only RelA, RelB, and c-Rel contain C-terminal transactivation domains
which allow transcriptional initiation (Hayden & Ghosh, 2012). All NF-κB family
members share a Rel homology domain which mediates dimerization, interaction with its
inhibitor, and DNA binding (Hayden & Ghosh, 2012). Since the initial discovery of NFκB, its involvement during development and inflammation induction, response, and
resolution have been researched in depth.

1.5.1 Classical and alternative NF-κB signaling
NF-κB signaling is generally defined as either the classical (canonical) or
alternative (non-canonical) pathway. In the classical NF-κB pathway, NF-κB can be
activated in B cells through various mechanisms such as through TLR, BCR, or
proinflammatory cytokine stimulation (Li & Verma, 2002; Weil & Israel, 2004). A
signaling cascade leads to phosphorylation of IκB by the IKK complex, which is
recognized by ubiquitin ligase machinery, polyubiquitinated, and targeted for
proteasomal degradation like previously described in section 1.3 Toll-Like Receptor. In

24

the alternative pathway, NF-κB is activated through TNF receptor (TNFR) family
members such as B cell-activating factor (BAFF) receptor (Claudio et al, 2002) and
CD40 (Homig-Holzel et al, 2008). Activation through TNFR family members leads to the
activation of NF-κB-inducing kinase (NIK), which leads to the phosphorylation,
ubiquitination, and processing of p100 to activate RelB/p52 NF-κB complexes (Sun,
2011). The heterodimerization of NF-κB subunits activated predominantly by each
pathway allows crosstalk between classical and alternative NF-κB signaling.

1.5.2 Mouse models of NF-κB and the roles of NF-κB in B cells
Various NF-κB/Rel complexes are expressed during different developmental
stages of B cells. In pre-B cells, p50/p65 is the primary inducible complex, p50/Rel is the
predominant complex in mature B cells, and p52/RelB appears to be the dominant
complex in plasma cells (Liou et al, 1994). Mice deficient for various NF-κB family
members have been generated (Table 1.2), and have been used to elucidate the
developmental and functional roles of each family member in B cells. With the exception
of Rela, germline deletion of a single NF-κB family member does not result in embryonic
lethality. Early death in germline Rela null embyros (~E15) is caused by excessive
apoptosis of hepatocytes (Beg et al, 1995; Doi et al, 1999). Adoptive transfer of Rela-/fetal liver cells into lethally irradiated Rag1-/- mice can lead to the generation of
lymphocytes, but B cell development is significantly impaired as a result of sensitivity to
TNF-α induced cell death (Prendes et al, 2003). Relb null mice have multiple
immunological abnormalities, including impaired dendritic cell development, an
expansion of myeloid cells in the spleen and bone marrow, and multi-organ inflammation
caused by T cell infiltration (Weih et al, 1995; Weih et al, 1996). Relb-/- mice have
normal Ig secretion abilities, but have impaired proliferation upon stimulation through
TLR4, BCR, or CD40 (Snapper et al, 1996a). Rel deletion results in proliferative defects
in response to LPS, anti-IgM or CD40L stimulation; in addition, there is an impairment in
both basal and secondary antibody production (Kontgen et al, 1995). In Nfkb1-/- mice,
there is impaired LPS mediated B cell proliferation and isotype switching (Sha et al,
1995). Nfkb1, Rela, Relb and Rel, are involved with MZ B cell, but not FO B cell
development (Cariappa et al, 2000; Weih et al, 2001). Lastly, Nkfb2 null mice have the
most profound B cell phenotype. Nfkb2-/- mice have reduced MZ, FO, T1, and T2 B cells
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in the spleen (Guo et al, 2007). Furthermore, there is a reduction of B cells in the bone
marrow and lymph nodes, and Nfkb2-/- mice have impaired germinal center formation and
T-dependent antibody responses (Caamano et al, 1998; Franzoso et al, 1998).
It is likely that there is functional compensation between NF-κB family members,
since germline deletion of multiple transcription factors results in a more severe
phenotype than deleting a single factor. For example, proliferation in response to LPS or
anti-IgM, antibody production, and germinal center formation is further impaired in
Nfkb1-/-Rel-/-mice, and B cells are more apoptotic when stimulated compared to either
Nfkb1-/- or Rel-/- mice (Pohl et al, 2002). Moreover, B cells fail to progress past the T1
stage in Nfkb1-/-Nfkb2-/- mice (Claudio et al, 2002), whereas differentiation past the T1
stage is possible in Nfkb1-/- or Nfkb2-/- mice. Overall, activation of NF-κB is an important
component of B cell development and function.
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Table 1.2. Phenotype of NF-κB family member null mutations in mice
Mutated

Phenotype in knockout mice

References

gene
Rela

- Embryonic lethal (~E15)

(Beg et al,
1995)

- TNF-α induced apoptosis of hepatocytes

Relb

- Required for MZ B cell development

(Cariappa et al,
2000)

- Impaired dendritic cell development

(Weih et al,
1995; Weih et
al, 1996)

- Expansion of myeloid cells in the spleen and bone
marrow
- Multi-organ inflammation caused by T cell
infiltration

Rel

- Impaired B cell proliferation upon stimulation
through TLR4, BCR, or CD40

(Snapper et al,
1996a)

- B cell proliferative defects following LPS, anti-IgM
or CD40L stimulation

(Kontgen et al,
1995)

- Impaired antibody production at the basal level, and
upon secondary immune response
- Required for MZ B cell development

Nfkb1

- Impaired LPS mediated B cell proliferation and
isotype switching
- Required for MZ B cell development

Nfkb2

- Reduced MZ, FO, T1, T2 B cell numbers in the
spleen
- Impaired germinal center formation
- Impaired T-dependent antibody responses

(Cariappa et al,
2000)
(Sha et al,
1995)
(Cariappa et al,
2000)

(Guo et al,
2007)
(Caamano et al,
1998; Franzoso
et al, 1998)
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1.6 E26 Transformation Specific (ETS) Transcription Factors
The ETS name is derived from the E26 avian erythroblastosis virus which carried
the v-ets oncogene (Sharrocks, 2001). Proteins in the ETS family share an evolutionarily
conserved DNA-binding domain, which forms a winged loop-helix-loop structure to bind
purine rich consensus motifs containing the core sequence GGAA/T (Ciau-Uitz et al,
2013; Sharrocks, 2001). Members of the ETS transcription factor family are involved
with the regulation of a variety of genes involved with growth, activation, and
development in adults and embryos of many organisms (Sharrocks, 2001; Wasylyk et al,
1993). Adding to the complexity of transcriptional regulation, ETS proteins can function
in collaboration with other transcription factors in the activation or repression of target
genes (Sharrocks, 2001). This thesis focuses on the ETS transcription factors PU.1, SpiB, and Spi-C, which belong to the Spi subfamily, and how each is involved with
transcriptionally regulating genes involved with B cell development and function. Figure
1.5 demonstrates the structural similarities between PU.1, Spi-B, and Spi-C. All three
transcription factors contain an N-terminal activation domain rich in acidic amino acids
(ACID), and have similar amino acid homology within the DNA binding domain (DBD).
PU.1 contains a Gln-rich (Q) region believed to be necessary for transactivation. The
proline, glutamic acid, serine, and threonine (PEST) sequence contained within PU.1 and
Spi-B are known to interact with interferon regulatory factor (IRF) family transcription
factors, and is suggested to be involved with protein degradation (Brass et al, 1999;
Rogers et al, 1986). Summarized in Table 1.3 are the phenotypes of mice containing
germline deletions of PU.1, Spi-B, or Spi-C.

1.6.1 PU.1
PU.1 was identified in 1988 as an oncogene from the proviral insertion of the
Friend spleen focus forming virus into the Spi-1 locus, which induced murine
erythroleukemia (Moreau-Gachelin et al, 1988). In mice, PU.1 is encoded by the Spi1
gene and is located on chromosome 2, whereas in humans, PU.1 is encoded by SPI-1 and
is located on chromosome 11. PU.1 is expressed in most hematopoietic cells, including
macrophages, granulocytes, dendritic cells (DCs), B cells, and T cells (Carotta et al,
2010). With over 110 direct target genes identified to date (Turkistany & DeKoter, 2011),
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PU.1 has been the most well-studied ETS transcription factor. The genes regulated by
PU.1 include antibodies and their receptors, and cytokines and their receptors involving
inflammation, leukocyte growth, and development (Turkistany & DeKoter, 2011). Of all
the ETS transcription factors, Spi1 defects have the most profound effects on normal
hematopoiesis (Bartel et al, 2000). Targeted disruption of Spi1 was first generated by
Scott et al. in 1994 by deleting the PU.1 DNA binding region in exon 5 of the Spi1 gene
(Scott et al, 1994). Germline knock-out mice for the Spi1 gene (PU.1-/-) are unable to
produce any lymphoid and myeloid cells during fetal hematopoiesis, and are also latestage embryonic lethal (Scott et al, 1994). However, erythroid progenitors and
megakaryocytes are still generated in PU.1-/- fetuses (Scott et al, 1994). Colony forming
assays using fetal liver cells from embryonic day 14.5 (E14.5) PU.1-/- mice failed to
generate macrophage, granulocyte, or B cell colonies in vitro (Scott et al, 1997).
Furthermore, transplantation of fetal liver cells from PU.1-/- mice into lethally irradiated
C57BL/6 mice failed to reconstitute cells from the lymphoid and myeloid lineages,
further demonstrating the requirement of PU1 in these cell types (Scott et al, 1997). In
1996, McKercher et al generated a germline Spi1 null mice using a targeted insertional
disruption of the PU.1 DNA binding domain (McKercher et al, 1996). One major
difference in these Spi1 null mice was that they were viable at birth, but died within two
days as a result of septicemia (McKercher et al, 1996). Mice could survive for up to 17
days if maintained on antibiotics, and T cell generation was observed 3-5 days after birth,
suggesting a delay in T cell development (McKercher et al, 1996). Differences observed
between Spi1 null mice between Scott et al. and McKercher et al. are likely due to
differences in their deletion strategy of the Spi1 gene. Nonetheless, similar to the findings
by Scott et al., Spi1 null neonates generated by McKercher et al. produced no mature
macrophages, neutrophils, B cells, and T cells (McKercher et al, 1996). Therefore, PU.1
is critical for the development and differentiation of cells of both the innate and adaptive
immune system.
The expression level of PU.1 has effects on hematopoietic cell fate decisions.
High concentrations of PU.1 promote macrophage differentiation, whereas low levels of
PU.1 favor B cell differentiation (DeKoter & Singh, 2000). High expression of PU.1
occurs in HSCs and CLPs (Back et al, 2005; Nutt et al, 2005), but PU.1 expression is
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Table 1.3. Phenotypes of mice containing germline deletions for ETS transcription
factors
Mutated

Phenotype in knockout mice

References

gene
Spi1 (Scott et
al. 1994)

- Embryonic lethal (E17.5-18)
- No commitment to B cells, monocytes, dendritic
cells, neutrophils

Spi1
(McKercher
et al. 1996)

- Post-natal viable for 48 h; viable up to 17 days if
maintained on antibiotics

(Scott et al,
1997; Scott et
al, 1994)

(McKercher et
al, 1996)

- Delayed T cell development (when treated with
antibiotics)
- No mature macrophages, neutrophils, B cells,
and T cells in neonatal mice
Spib

- Viable, fertile

(Su et al, 1997;
Su et al, 1996)

- Fewer B cells; impaired BCR signaling,
proliferative defect upon BCR stimulation,
impaired secondary antibody responses
- Defect in generation of intestinal microfold (M)
cells; impaired uptake of pathogens
- Impaired plasmacytoid dendritic cell
development; impaired IFN production through
TLR7 and TLR9 stimulation
Spic

- Viable
- Defect in development of red pulp macrophages

(Kanaya et al,
2012; Sato et al,
2013)
(Sasaki et al,
2012)

(Kohyama et al,
2009)
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reduced during commitment to the B cell lineage (Nutt et al, 2005). Although B cells
express decreased levels of PU.1 upon differentiation, a certain threshold of expression is
still required for proper B cell development. Mice generated with a hypomorphic allele of
Spi1 (Spi1BN/BN), expressing a 5-fold reduction of PU.1 compared to WT in pro-B cells,
were unable to generate B cells in the spleen or fetal liver (Houston et al, 2007).
Furthermore, Spi1BN/BN fetal liver progenitor cells transplanted into sub-lethally irradiated
Rag2-/-Il2rg-/- mice failed to generate B cells in the spleen and bone marrow of recipient
mice (Houston et al, 2007). Conditional knockout mouse models for PU.1 were generated
to further investigate the role of PU.1 on B cell development and function (Polli et al,
2005). PU.1 is essential specifically during the early stages of B cell development, since
deletion of Spi1 in committed B cell progenitors has no effect on B cell maturation, and
has minimal effects on T-dependent responses (Polli et al, 2005). Overall, a sufficiently
high level of PU.1 is required during HSC to pro-B cell differentiation, but PU.1 is not
essential following B cell commitment.

1.6.2 Spi-B
The second Spi subfamily member is Spi-B, which was identified by probing a
cDNA library generated from Raji Burkitts lymphoma cells with the PU.1 ETS DNAbinding domain (Ray et al, 1992). Spi-B has been mapped to chromosome 19 in humans
and to chromosome 7 in mice (Peters et al, 1997; Ray et al, 1992). Spi-B and PU.1 are
highly conserved in humans, sharing 43% amino acid similarity with overall, and 67%
similarity in its ETS domain (Ray et al, 1992) (Figure 1.5). Expression of Spi-B was
initially believed to be exclusive to the B cells and T cells (Su et al, 1996), however,
more recent studies have demonstrated a role for Spi-B in plasmacytoid dendritic cells
(pDCs) (Sasaki et al, 2012) and intestinal microfold cells (Kanaya et al, 2012; Sato et al,
2013). Germline Spi-B knockout mice (Spib-/-) are viable and possess mature B and T
cells, potentially due to its degree of redundancy with PU.1. Although the functionality of
Spib-/- T cells appears to be normal, Spib-/- B cells have defects in functional and humoral
responses (Su et al, 1997). Spib-/- B cells which are stimulated in vitro with anti-IgM
demonstrate poor proliferation with increased rates of apoptosis. Furthermore, Spib-/mice immunized with dinitrophenol conjugated to keyhole limpet hemocyanin (DNP-
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KLH) produce low levels of IgG1, IgG2a and IgG2b, and are unable to sustain germinal
centers (Su et al, 1997). Therefore, Spi-B is required for BCR-mediated responses in vitro
and in vivo.
Since Spi-B recognizes the same binding sites as PU.1 (Ray et al, 1992) and can
activate the same reporter gene constructs in vitro (Muller et al, 1996; Ray et al, 1992; Su
et al, 1996), it strengthened the hypothesis that both Spi-B and PU.1 have partial
functional redundancy. To determine the function of both PU.1 and Spi-B in B cells,
mice heterozygous for Spi1 were crossed to Spib-/- to generate Spi1+/-Spib-/- (PU.1+/-Spib-/; PUB) mice (Garrett-Sinha et al, 1999), since complete PU.1 deletion resulted in
embryonic lethality (Scott et al, 1994). Many of the deficiencies observed in the Spib-/phenotype were further impaired by the additional reduction of PU.1. PUB mice had
fewer B cells than Spib-/- mice, increased basal levels of apoptotic B cells, further
impaired anti-IgM and LPS-mediated B cell proliferation, and reduced BCR signaling
(Garrett-Sinha et al, 1999). Therefore, both PU.1 and Spi-B are required for normal BCR
signal transduction, and function in a semi-redundant or complementary manner.
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Figure 1.5. Major domains of the SPI-group ETS transcription factors.
The percentages indicate the amino acid sequence homology of the ETS DNA binding
domain (DBD) between the three transcription factors. The acidic transactivation
domains are denoted ACID. PU.1 and Spi-B has a glutamine (Q) rich and a
proline/serine/threonine (PST) rich domain following the ACID domain respectively.
PU.1 and Spi-B also have a proline/glutamic acid/serine/threonine (PEST) domain prior
to the DBD.
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1.6.3 Spi-C
Spi-C is encoded by the Spic gene located on chromosome 10 in mice, and 12 in
humans, and was initially discovered via a yeast one-hybrid screening of a cDNA library
made from LPS stimulated splenic B cells (Bemark et al, 1999; Carlsson et al, 2002). A
second group discovered the same protein and published their findings months later, but
identified it as PU.1-related factor (Prf) (Hashimoto et al, 1999). Spi-C is expressed in B
cells, macrophage, and dendritic cell populations in the spleen, bone marrow, and lymph
nodes according to Northern blot analysis (Bemark et al, 1999). Based on amino acid
sequence homology in its DNA binding ETS domain, Spi-C is related to Spi-B and PU.1
(Figure 1.5). Spi-C is also capable of binding to the GGAA/T motif similar to PU.1 and
Spi-B. However, there is a preference for an A in position -2 (two nucleotides before the
GGAA core) for Spi-C (Bemark et al, 1999), whereas PU.1 prefers G at the -2 position
(Ray-Gallet et al, 1995). Similar to PU.1 and Spi-B, Spi-C contains an acidic
transactivation domain at the N-terminal which is conserved between species (Carlsson
et al, 2003). However, Spi-C differs from PU.1 and Spi-B as it contains a much longer
C-terminus relative to the ETS binding site (Carlsson et al, 2003). In addition, Spi-C does
not interact with IRF-4 in vitro, suggesting that Spi-C has functionally distinct roles
compared to PU.1 and Spi-B (Carlsson et al, 2003).
In B cells, Spi-C is highly expressed in the mature B cell populations, but is
absent in the pre-B and plasma cell stages (Bemark et al, 1999). There are few target
genes known for Spi-C in B cells. Spi-C has been reported to directly transcribe Fcer2a
(DeKoter et al, 2010), and can cooperate with STAT6 to directly induce transcription of
IgE (Carlsson et al, 2006). Ectopic expression experiments that overexpressed Spi-C in
either cultured pro-B cells using a retroviral vector (Schweitzer et al, 2006), or in mice
using a B cell specific transgene (Zhu et al, 2008), suggested that Spi-C functions as a
negative regulator of transcription by opposing PU.1 and/or Spi-B activity. However,
whether this opposition was due to direct competition for binding was not determined.
Recently a Spic knockout mouse was generated making it possible to determine the effect
of loss of function of Spi-C (Kohyama et al, 2009). Analysis of Spic-/- mice revealed that
Spi-C is essential for the generation of red pulp macrophages in the spleen and is
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inducible by Heme (Haldar et al, 2014). However, the role of Spi-C in B cell
development and function was not examined closely in these mice.

1.7 Thesis Overview
This thesis characterizes the transcriptional regulation of BCR and TLR
expression and signal transduction in B cells by the related ETS transcription factors
PU.1, Spi-B, and Spi-C. Specifically, the mechanism by which PU.1, Spi-B, and Spi-C
regulate the transcriptional activity of Nfkb1 in B cells is elucidated. The primary
objective of this study was to determine the function of PU.1, Spi-B, and Spi-C during B
cell development, and during TLR-mediated responses. It was hypothesized that PU.1
and Spi-B were required for positively regulating components of TLR responses, and
Spi-C inhibited PU.1 and Spi-B targets.

1.7.1 Chapter 2: Nfkb1 activation by the ETS transcription factors PU.1
and Spi-B promotes Toll-Like receptor-mediated splenic B cell
proliferation
In this study, we found impairment in the ability of PUB B cells to proliferate in
response to different TLR ligands. The impairment in proliferation was not due to a
failure of activation or increased rates of apoptosis upon stimulation in PUB B cells.
Transcript levels of genes associated to the TLR signaling pathway were measured, but
despite decreased transcript levels of multiple genes of interest in PUB B cells, most were
not sufficient to explain our phenotype when tested at the protein level. Nevertheless,
decreased transcript levels of Nfkb1, and lower levels of its encoded protein p50 in PUB
B cells were detected. P50 is activated upon TLR stimulation, and Nfkb1-/- B cells have a
proliferative phenotype in response to TLR ligands which is strikingly similar to PUB B
cells. It was hypothesized that PU.1 and Spi-B were involved with transcriptionally
regulating the Nfkb1 gene. It was determined that PU.1 and Spi-B directly activated
Nfkb1 transcription, and were essential for proper TLR-mediated responses. Our results
demonstrated that PU.1 and Spi-B regulated TLR responses in B cells, which is an
important auxiliary pathway involved in neutralizing antibody formation.
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1.7.2 Chapter 3: Identification of a negative regulatory role for Spi-C in the
murine B cell lineage
The role of Spi-C in B cell development and function was examined in this study.
In order to determine whether Spi-C and Spi-B were functionally redundant, a novel
mouse line was generated that was germline knockout for Spib and heterozygous for Spic
(Spib-/-Spic+/-). Spib-/- B cells are defective in BCR signaling, and have reduced FO B
cells compared to WT mice. Many aspects of the Spib-/- B cell phenotype were rescued in
Spib-/-Spic+/- B cells, including a restoration in FO and T2 B cells, and restored
proliferation in response to LPS and anti-IgM. The phenotypic rescue in Spib-/-Spic+/mice was attributed to elevated transcript levels of Nfkb1. It was hypothesized that Spi-C
was inhibiting Spi-B during transcriptional activation of Nfkb1. It was determined that
Spi-C directly binds to the Nfkb1 promoter to inhibit Spi-B’s transcriptional activation of
Nfkb1. Our results demonstrate a novel mechanism for Spi-C in opposing Spi-B in B cell
development and function.
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Chapter 2

2

Nfkb1 activation by the ETS transcription factors PU.1 and
Spi-B promotes Toll-Like receptor-mediated splenic B cell
proliferation
Generation of antibodies against T-independent and T-dependent antigens

requires Toll-Like receptor (TLR) engagement on B cells for efficient responses.
However, regulation of TLR expression and responses in B cells is not well understood.
PU.1 and Spi-B (encoded by Spi1 and Spib respectively) are transcription factors of the
E26-transformation-specific (ETS) family, and are important for B cell development and
function. It was found that B cells from mice knockout for Spi-B and heterozygous for
PU.1 (Spi1+/-Spib-/-, PUB mice) proliferated poorly in response to TLR ligands compared
to WT B cells. The NF-κB family member p50 (encoded by Nfkb1) is required for LPS
responsiveness in mice. PUB B cells expressed reduced Nfkb1 mRNA transcripts and p50
protein. The Nfkb1 promoter was regulated directly by PU.1 and Spi-B as shown by
reporter assays and chromatin immunoprecipitation analysis. Occupancy of the Nfkb1
promoter by PU.1 was reduced in PUB B cells compared to WT B cells. Finally,
infection of PUB B cells with a retroviral vector encoding p50 substantially restored
proliferation in response to LPS. We conclude that Nfkb1 transcriptional activation by
PU.1 and Spi-B promotes TLR-mediated B cell proliferation.

2.1 Introduction
Toll-Like receptors expressed by B cells recognize conserved microbial products.
Engagement of TLR-ligands by B cells is required for thymus-independent responses that
are sufficient to promote CSR, proliferation, and antigen presentation (Browne, 2012;
Pone et al, 2010). Generation of optimal T-dependent antibody responses also requires
TLR signaling in B cells (Pasare & Medzhitov, 2005; Ruprecht & Lanzavecchia, 2006).
For example, efficient antibody responses to protein antigens after immunization with
synthetic nanoparticles required engagement of TLRs on B cells (Kasturi et al, 2011).
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Therefore, identifying factors controlling TLR expression and responses in B cells has
important implications for the generation of neutralizing antibody responses.
Mature murine B cells express and respond to TLR1, TLR2, TLR4, TLR6,
TLR7/8, and TLR9 ligands (Genestier et al, 2007; Gururajan et al, 2007; Hornung et al,
2002), resulting in NF-κB activation through MyD88 or TRIF-dependent pathways
(Kawai & Akira, 2006). NF-κB activates genes involved in cytokine synthesis, antibody
secretion, and cell proliferation (Bekeredjian-Ding & Jego, 2009). The NF-κB family
includes p105 that is processed into p50 (encoded by Nfkb1), p100 that is processed into
p52 (encoded by Nfkb2), RelA (p65), Rel (c-Rel), and RelB, which all interact with DNA
as hetero- or homodimers (Hayden & Ghosh, 2008). Optimal TLR signaling in B cells
may require MHC class II (MHCII) interaction with Bruton’s tyrosine kinase (Btk) and
CD40 (Liu et al, 2011). However, many aspects of gene regulation involving TLR
expression and signal transduction in B cells remain unclear.
PU.1 and Spi-B are E26 transformation-specific (ETS)-family transcription
factors encoded by Spi1 and Spib respectively, and are important in B cell development
and function (DeKoter et al, 2010). PU.1 is expressed in most hematopoietic cell types,
directly regulating many genes involved in cellular communication (Turkistany &
DeKoter, 2011). Spi-B is expressed in B cells, plasmacytoid dendritic cells, and at lower
levels in T cells (Su et al, 1996). PU.1 and Spi-B share 67% amino acid homology in
their DNA binding domain and can bind an identical consensus sequence containing the
core motif 5'-GGAA-3' (Dahl et al, 2002; Pio et al, 1996; Ray-Gallet et al, 1995). Both
transcription factors are expressed in B cells, regulate common target genes, and are
functionally redundant (Sokalski et al, 2011; Xu et al, 2012). Spi1-/- mice die during
embryogenesis and produce no B cells (Scott et al, 1994). In contrast, viable Spib-/- mice
have fewer B cells, which are defective in BCR signaling and are unable to generate
antibody responses to T-dependent antigens (Garrett-Sinha et al, 1999). Spi1+/- Spib-/(PUB) mice have greater impairment in B cell numbers and BCR signaling compared to
Spib-/- or Spi1+/- mice (Garrett-Sinha et al, 1999; Su et al, 1997), and also have reduced
follicular (FO) and increased marginal zone (MZ) B cell frequencies compared to WT
mice (DeKoter et al, 2010). Therefore, PU.1 and Spi-B are critically important for B cell
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development and BCR signaling, but it remains unclear what these transcription factors
regulate downstream to explain this phenotype.
In this study, it was determined whether PU.1 and Spi-B regulate innate immune
responses in B cells. Impairment in TLR-mediated proliferation in PUB B cells was
observed. Gene and protein expression analysis, luciferase reporter assays, and chromatin
immunoprecipitation (ChIP) experiments demonstrated that PU.1 and Spi-B directly
activate Nfkb1 encoding p50. Infection of PUB B cells with a retroviral vector encoding
p50 significantly increased proliferation in response to LPS. Therefore, decreased P50
expression is sufficient to explain many aspects of the PUB B cell phenotype. Our results
suggest that PU.1 and Spi-B are important transcriptional regulators of TLR responses in
B cells.

2.2

Results

2.2.1 PUB mice exhibit impaired TLR-mediated B cell proliferation
PUB B cells were previously reported to have reduced proliferation in response to
anti-IgM or lipopolysaccharide (LPS) (Garrett-Sinha et al, 1999). To determine if
impaired proliferation was limited to LPS (TLR4 ligand), splenic B cells were enriched
by CD43 depletion and cultured with various TLR ligands. Compared to WT B cells,
PUB B cells proliferated poorly at all tested concentrations of LPS (Fig. 2.1A) or CL097
(TLR7/8 ligand) (Fig. 2.1B), and proliferated poorly to Pam3CSK4 (TLR2/1), FSL1
(TLR6/2), ODN1826 (TLR9) (Fig. 2.1C), or anti-IgM (Fig. 2.1D-E) stimulation. Both
WT and PUB B cells failed to respond to flagellin (TLR5) and Poly(I:C) LMW or HMW
(TLR3) (Fig. 2.2B), but proliferated nearly equally well in response to anti-CD40 or
LPS+anti-CD40 stimulation (Fig. 2.2C-D), which indicated no general proliferation
impairment in PUB B cells. Anti-CD40 stimulation did not restore responsiveness of
PUB B cells to anti-IgM (Fig. 2.2C-D). Interestingly, although PUB B cells proliferated
poorly in response to anti-IgM or LPS stimulation alone, LPS+anti-IgM stimulation
resulted in equivalent WT and PUB proliferation (Fig. 2.1F-G). Similar results were
obtained using 3-[4, 5-dimethylthiazol-2yl]-2, 5-diphenyl-tetrazolium bromide (MTT)
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proliferation assays and [3H]-thymidine incorporation assays (Fig. 2.2D). Overall, these
results suggested that proper PU.1 and Spi-B expression was required for TLR-mediated
B cell proliferation.
Altered splenic B cell composition could explain proliferative defects in PUB B
cells. However, PUB mouse spleens have increased ratios of MZ to FO B cell frequencies
(DeKoter et al, 2010) and MZ B cells were shown to have greater TLR-mediated
proliferative potential compared to FO B cells (Oliver et al, 1997). Former studies
reported reduced B cell frequencies in PUB spleens (Garrett-Sinha et al, 1999), which
was confirmed by our study (Fig. 2.3A-B). PUB spleens contained elevated frequencies
of CD11b+GR1+ myeloid cells, but the absolute number of CD11b+GR1+ splenocytes
were slightly reduced compared to WT mice (Fig. 2.3C-D). Flow cytometric analysis of
CD19hiCD1dhiCD5+ B regulatory cells (Yanaba et al, 2008) revealed no significant
difference in frequency between PUB and WT spleens (Fig. 2.3E). Furthermore, spleens
from PUB mice contained fewer cells than WT mice (Fig. 2.3F). Elevated B cell
activating factor (BAFF) is common in B cell lymphopenia (Kreuzaler et al, 2012), and
conceivably could impede TLR-mediated proliferation. Steady-state levels of serum
BAFF were found to be elevated in PUB mice compared to WT (Fig. 2.4A). BAFF
receptor (BAFF-R) expression was reduced on PUB B cells (Fig. 2.4B), consistent with
what was expected from higher BAFF levels (Kreuzaler et al, 2012). To determine if
increased BAFF could impair PUB B cell proliferation, splenic B cells were LPS
stimulated with and without recombinant BAFF. Additional BAFF increased proliferation
in both untreated or LPS treated groups in WT and PUB B cells (Fig. 2.4C). Therefore,
impaired TLR-mediated PUB B cell proliferation was not explained by altered B cell
composition or elevated BAFF levels.
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Figure 2.1. Impaired TLR-mediated proliferation in PUB (Spi1+/-Spib-/-) B cells.
(A and B) B cells from PUB mice responded poorly compared to WT stimulated with
different concentrations of LPS (A) and CL097 (B). Y-axis indicates OD570, and X-axis
indicates concentrations of agonists. (C) B cells from PUB mice responded poorly
compared to WT stimulated with indicated TLR9, TLR6/2, TLR4, and TLR2/1 ligands.
(D) Impaired PUB B cell proliferation in response to anti-IgM stimulation. (E)
Quantitation of four independent experiments as done in D. Proliferation indices were
calculated by normalizing OD570 of treatments to WT untreated. For A-E, B cell
proliferation was assessed by MTT proliferation assay following 72 h stimulation. Data
shows the mean ± SD for triplicate wells for A-D and are representative of at least two
independent experiments. Values in E are shown as mean ±SEM (n=4). *p<0.05;
**p<0.01; ***p<0.001.
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Figure 2.2. Proliferation of WT and PUB splenic B cells in response to various stimuli.
(A) B cells were enriched by magnetic depletion and purity was determined by
CD19+B220+ flow cytometry analysis (box). (B) Neither WT nor PUB splenic B cells
proliferated in response to TLR3, TLR5, and TLR7 ligands. Proliferation was assessed
with the presence of different TLR ligands for 72 h in a 96-well plate using a MTT cell
proliferation assay. Values are shown as mean ± standard deviation of triplicate wells.
Data are representative of at least two independent experiments. (C and D) Ex vivo
stimulation with LPS and anti-IgM, results in impaired B cell proliferation in PUB mice.
Proliferation was measured in splenic PUB and WT B cells following 72 h stimulation
with different combinations of LPS (10 μg/mL), anti-CD40 (10 μg/mL), and anti-IgM (50
μg/mL). Proliferation was assessed using a (C) MTT cell proliferation assay or (D) [3H]thymidine incorporation assay. [3H]-thymidine (1 mCi/mL) was added to each well after
72 h stimulation, followed by scintillation counting 24 h after thymidine treatment. For
B-D, values are shown as mean ± standard deviation of triplicate wells, and are
representative of two independent experiments. Statistical analysis was performed using
Student's t-test, * = p<0.05, ** = p<0.01, *** = p<0.001.
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Figure 2.3. Splenic B and myeloid cell composition in PUB mice.
(A) Reduced B cell frequencies in the spleen of PUB mice. Flow cytometric analysis was
performed to determine the frequency of B cells expressing CD19 and B220 in WT and
PUB mice. Dashed box represents B cells in the spleen. Shown is a representative
experiment of seven individual experiments. (B) Reduced CD19+ and B220+ cell
frequencies and absolute numbers in the spleens of PUB mice. Quantitation of the
frequency and absolute number of splenic B cells expressing CD19 and B220 (n=7). (C)
Increased frequency of myeloid cells in the spleens of PUB mice. Flow cytometric
analysis was performed to determine the frequency of myeloid cells expressing GR-1 and
CD11b in WT and PUB mice. Shown is a representative experiment of seven
independent experiments. (D) Increased frequency of myeloid cells, but decreased
absolute number of myeloid cells in the spleens of PUB mice. Flow cytometric analysis
was performed to determine the frequency and absolute numbers of splenic myeloid cells
expressing GR-1 and CD11b for 7 mice. (E) There is no difference between the
frequency of Breg (B10) cells between PUB and WT mice. Flow cytometric analysis was
performed to determine the frequency of B10 cells. B10 cells were gated on
CD19hiCD1d+CD5+ (bolded quadrant). Shown is a representative experiment of two
independent experiments. (F) Reduced absolute number of total splenocytes in PUB mice
compared with C57BL/6 mice. Shown are total splenic cell counts WT and PUB mice
(n=7). For all panels, *, P<0.05; **, P<0.01; ***. P<0.001. Error bars represent standard
deviation.
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Figure 2.4. Proliferation of splenic B cells in response to recombinant BAFF and
analysis of BAFF-R and BAFF serum levels.
(A) Elevated BAFF levels were detected in sera from PUB compared to WT mice by
ELISA. Values are shown as mean ± standard deviation from six individual mice. Data is
representative of two independently performed experiments. (B) Reduced BAFF-R levels
on the surface of splenic B cells in PUB mice compared to WT mice. Mean fluorescence
intensities (MFIs) of BAFF-R was measured by flow cytometry on total CD19+ cells,
gated CD21hiCD19+ (MZ) B cells, or gated CD21intCD19+ (FO) B cells from WT and
PUB spleens. Data is shown as mean ± standard error mean of six independent
experiments. (C) Addition of recombinant BAFF (100 ng/mL) increased proliferation in
splenic WT and PUB B cells when treated with LPS, as compared with treatments
without BAFF. Proliferation was assessed following 72 h stimulation in a 96-well plate
using a MTT cell proliferation assay. Values are shown as mean ± standard error mean of
five independent experiments. For all panels, *, P<0.05; **, P<0.01.
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2.2.2 PUB B cells are activated following stimulation
We wanted to determine the mechanism of impaired TLR-mediated B cell
proliferation in PUB mice. To determine whether PUB B cells were capable of activation
by TLR ligands, MFI of CD25 or CD69 activation markers were measured on total
B220+ cells, or B cells with MZ (CD21hiB220+), or FO (CD21intB220+) phenotypes after
24 h LPS stimulation (Fig. 2.5A). All WT and PUB B cell subsets upregulated CD25
following LPS stimulation compared to untreated cells (Fig. 2.5B-C). Untreated FOphenotype PUB B cells expressed more CD25 than WT (Fig. 2.5C). Next, CD69
expression was measured 24 h after LPS stimulation (Fig. 2.5D-E). Both WT and PUB B
cells increased CD69 expression following LPS stimulation for all subsets (Fig. 2E).
CD69 was also measured 72 h post stimulation in total B220+ cells. PUB B cells failed to
upregulate CD69 to WT levels following 72 h LPS stimulation (Fig. 2.5F-G). In contrast,
PUB B cells expressed higher levels of CD69 following anti-IgM stimulation, and LPS +
anti-IgM stimulation resulted in equivalent expression between WT and PUB B cells
(Fig. 2.5F-G). In summary, PUB B cells were activated following LPS stimulation, but
CD69 upregulation was reduced compared to WT when measured at 72 h.
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Figure 2.5. Splenic PUB B cells are activated following LPS stimulation.
(A) Flow cytometry gating strategy on total B220+, MZ (CD21hiB220+), or FO
(CD21intB220+) B cells. (B) Histograms show increased CD25 expression following 24 h
LPS stimulation in WT and PUB B cells. (C) Quantitation of data shown in B. (D)
Histograms show increased CD69 expression following 24 h LPS stimulation in WT and
PUB mice. (E) Quantitation of data shown in D. (F) CD69 expression is lower in PUB
total B cells than WT total B cells at 72 h post stimulation with LPS. CD69 expression is
also shown for anti-IgM and LPS+anti-IgM conditions. (G) Quantitation of data shown in
F. Values in C, E, and G show the normalized CD25 or CD69 MFI ±SEM for five
independent experiments. Normalized MFI was calculated by dividing MFI values by
WT untreated MFI for each given subset. *p<0.05; **p<0.01.
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2.2.3 Apoptosis in PUB splenic B cells is not increased following LPS
stimulation
PUB B cells were previously reported to exhibit increased steady-state levels of
apoptosis (Garrett-Sinha et al, 1999). Therefore, impaired TLR-mediated PUB B cell
proliferation could be due to increased apoptotic cell death. To test this hypothesis, we
stained B cells for Annexin V and PI after 72 h incubation with or without LPS and/or
anti-IgM (Fig. 2.6A). Under the culture conditions used, a mean of 36% of WT B cells
were low/negative for Annexin V staining after anti-IgM stimulation, while a mean of 6%
of PUB B cells were low/negative for Annexin V staining after anti-IgM stimulation (Fig.
2.6A, 2.6C). Therefore few PUB B cells survived anti-IgM stimulation, in accord with
proliferation results shown in Fig. 2.1E. Frequencies of apoptotic (Annexin VhiPI-) PUB
B cells untreated or anti-IgM stimulated were significantly higher than WT controls; and
frequencies of live (Annexin V-PI-) PUB B cells untreated or anti-IgM stimulated were
significantly decreased compared to WT controls. However, frequencies of apoptotic
cells between LPS or LPS+anti-IgM treated WT and PUB B cells were similar (Fig.
2.6B). No significant difference was observed between live WT and PUB B cells
stimulated with LPS or LPS+anti-IgM. (Fig. 2.6C). Therefore, these results suggest that
reduced proliferation of PUB B cells in response to LPS was not primarily due to
increased apoptosis.

53

Figure 2.6. Apoptosis in PUB B cells is not elevated following LPS stimulation.
(A) Apoptosis was analyzed by flow cytometry using Annexin V and PI staining in
enriched B cells that were untreated or treated with indicated stimuli. (B) Quantitation of
apoptotic (Annexin Vhi PI-) cells. (C) Quantitation of live (Annexin V- PI-) cells. Data in
B and C show the mean ± SEM of four independent experiments. *p<0.05; **p<0.01;
***p<0.001.
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2.2.4 PUB mice have altered transcript and protein levels of genes involved
in TLR signaling
MZ B cells are more readily activated and proliferative than FO B cells after LPS
stimulation (Oliver et al, 1997; Snapper et al, 1993). Despite increased MZ B cells in
PUB mice (DeKoter et al, 2010), impaired proliferation occurred in splenic PUB B cells
for all MyD88 dependent TLR ligands compared to WT (Fig. 2.1B-C). Therefore,
components of the MyD88-dependent signaling pathway might be regulated by PU.1 and
Spi-B. To test this hypothesis, RNA was prepared from sorted MZ B cells from WT and
PUB mice. Steady-state levels of mRNA transcripts encoding components of the MyD88dependent signaling were measured by RT-qPCR analysis. We examined transcript levels
of downstream signaling components (Fig. 2.7A), TLRs and related receptors (Fig. 2.7B),
and NF-κB/Rel subunits (Fig. 2.7C). Significant reductions in Myd88, Cd14, Tlr8, Tlr7
and Nfkb1 transcripts were measured in PUB MZ B cells (Fig. 2.7A-C). Next, we
stimulated enriched total B cells with LPS for 16 h and assessed gene expression profiles
by RT-qPCR. Transcript levels of downstream TLR signaling genes were not
significantly different in PUB B cells compared to WT (Fig. 2.7D). Although steady-state
transcript levels of TLR and related receptors were reduced in PUB MZ B cells,
transcript levels of Tlr2, Cd14, and Tlr8 were higher in total LPS stimulated PUB B cells
(Fig. 2.7E). Lastly, LPS stimulated PUB B cells expressed lower transcript levels of Rel
and Nfkb1 (Fig. 2.7F).
MyD88 is the adapter protein utilized by all TLRs to which B cells responded in
our hands (Fig. 2.1). However, immunoblotting analysis showed MyD88 levels were
unchanged between PUB and WT enriched B cells (Fig. 2.8A). Despite elevated Cd14
transcripts in LPS stimulated PUB B cells, surface CD14 expression was equal to WT 72
h post LPS or anti-IgM stimulation, and was elevated when LPS+anti-IgM stimulated
(Fig. 2.8B). Therefore, our results suggest that altered levels of MyD88 and CD14 did not
account for defective TLR responses in PUB B cells.
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Figure 2.7. Measurement of steady-state and LPS stimulated transcript levels of TLR
signaling genes.
(A-C) Steady-state transcript levels of genes related to downstream TLR signaling (A),
TLRs and related receptors (B), and NF-B subunits (C) were measured in MZ B cells of
PUB and WT mice. (D-F) Transcript levels in total B cells following 16 h LPS
stimulation of genes related to downstream (D) TLR signaling, (E) TLRs and related
receptors, and (F) NF-B subunits. Analysis was performed on RNA prepared from MZ
B cells enriched by cell sorting, or total enriched B cells. RT-qPCR was used to
determine relative mRNA transcript levels in PUB B cells compared to WT B cells, after
normalizing to Gapdh or B2m. Y-axis indicates mean fold change ±SEM relative to WT
levels for three individual mice. Values of 1 (dashed line) indicate no difference in
transcript levels between PUB and WT B cells. *p<0.05; **p<0.01; ***p<0.001.
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Next, surface expression of TLRs and related receptors were examined by flow
cytometry. Reduced TLR2 and TLR1 was measured on freshly isolated MZ, FO, and
total B cells of PUB mice (Fig. 2.8C). LPS can also activate B cells through binding
RP105 (Nagai et al, 2012), but levels between WT and PUB B cells were equal (Fig.
2.8D). TLR signaling in B cells has been reported to involve MHCII, CD40, and Btk
interaction (Liu et al, 2011), and PU.1 activates the Btk promoter (Himmelmann et al,
1996). PU.1 also directly regulates the transcriptional coactivator CIITA, which regulates
MHCII genes (Yoon & Boss, 2010). Since PU.1 transcriptionally regulates genes
involved with TLR signaling, TLR-mediated B cell proliferation might be regulated by
PU.1 and/or Spi-B through these auxiliary pathways and interactions. Decreased gene
transcription in PUB mice could result in decreased protein, and consequently fewer
protein interactions required for TLR signaling. To test this hypothesis, we measured
protein levels of MHCII, CD40, and Btk. PUB B cells failed to upregulate surface
MHCII (Fig. 2.8E) or CD40 (Fig. 2.8F) following 72 h LPS or anti-IgM stimulation.
Immunoblotting analysis showed equal Btk protein expression between PUB and WT B
cells (Fig. 2.8G). Overall, decreased TLR responsiveness in PUB B cells was
accompanied by reduced TLR1 and TLR2 expression, and a failure to upregulate MHCII
or CD40. However, these observations were not sufficient to explain the PUB phenotype.
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Figure 2.8. PUB B cells have decreased basal surface expression of TLR1 and TLR2 and
cannot upregulate MHCII and CD40 expression following stimulation.
(A) Immunoblotting for MyD88 and -actin was performed using total spleen cells (top
panel) or enriched B cell lysates (lower panel) from WT and PUB mice. (B) CD14
expression is increased in PUB B cells following LPS+anti-IgM stimulation, but not
increased when stimulated with LPS or anti-IgM. (C) PUB B cells have decreased TLR1
and TLR2 expression. TLR1 and TLR2 MFI was measured for gated MZ (CD21hiB220+),
FO (CD21intB220hi), and total B220+ B cells using flow cytometry. Data shows the mean
±SEM (n=5). (D) RP105 surface levels are equivalent between WT and PUB B cells.
RP105 MFI was measured for MZ, FO, and total B220+ cells using flow cytometry. Data
shows the mean ±SEM (n=3). PUB B cells fail to upregulate (E) MHCII expression or
(F) CD40 expression following LPS, anti-IgM, or LPS+anti-IgM stimulation. (G)
Immunoblotting for Btk, and -actin was performed using enriched B cell lysates from
WT and PUB mice. Immunoblotting experiments are shown as a representative of two
individual mice. For B, E, and F, enriched B cells were stimulated for 72 h before
analysis of CD14, MHCII, and CD40 expression by flow cytometry. Values represent
MFIs of total B cells expressing the indicated markers, normalized to untreated WT B
cells. Normalized MFIs were calculated by dividing MFI values by the WT untreated
MFI. Data shows the mean ±SEM of four independent experiments. *p<0.05; **p<0.01.
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2.2.5 Direct Nfkb1 promoter activation by PU.1 and Spi-B
Steady-state levels of Rel and Nfkb1 mRNA transcripts were expressed at reduced
levels in PUB B cells stimulated with LPS compared to WT B cells (Fig. 2.7F). It was
previously shown that Rel is regulated by PU.1 and/or Spi-B in B cells (Hu et al, 2001).
Nfkb1 encodes for p50 and is required for murine B cell proliferation in response to LPS
or anti-IgM (Sha et al, 1995). Reduced p50 expression could sufficiently explain many
aspects of the PUB phenotype. Immunoblotting analysis confirmed lower p50 levels in
splenic PUB B cells (Fig. 2.9A). We therefore investigated the role of reduced Nfkb1 in
PUB B cell proliferation.
PU.1 and Spi-B can interchangeably bind sites of target genes (Ray-Gallet et al,
1995). To determine locations of binding similarity between PU.1 and Spi-B, genomewide ChIP-sequencing (ChIP-seq) was performed using anti-FLAG Ab on WEHI-279 B
cell lymphoma cells overexpressing either 3X-FLAG tagged PU.1 or Spi-B. Both PU.1
and Spi-B were enriched at the Nfkb1 promoter (Fig. 2.9B). To determine whether PU.1
and Spi-B regulate Nfkb1 directly, we aligned the murine Nfkb1 promoter sequence from
multiple species, using a published transcription start site (TSS) for reference (Cogswell
et al, 1993). At the promoter, a 213 bp region was found to be 87% conserved between
multiple species, with exception to the 67% conservation of the Tasmanian Devil
sequence (Fig. 2.9C). Potential PU.1/Spi-B transcription factor binding sites were
predicted using MatInspector software. Three conserved binding sites with a matrix
similarity score >0.9 were predicted among all species, and a lower scoring fourth site
was identified near the TSS (Fig. 2.9C). Next, luciferase assays were used to determine
PU.1 and Spi-B’s contribution to Nfkb1 transcriptional activation. The conserved Nfkb1
mouse promoter region was cloned and tested by transient transfection in WEHI-279
cells. Site directed mutagenesis was performed on the predicted PU.1/Spi-B binding sites
of the two closest sites of the TSS of the promoter, by substituting GGAA (TTCC on
complement strand) binding site to GGAC (GTCC) (Fig. 2.9D), which was previously
reported to abolish PU.1 binding (DeKoter et al, 2010; Xu et al, 2012). Transcriptional
activation was detected at the Nfkb1 promoter, and mutation of PU.1/Spi-B sites
significantly reduced transcriptional activation (Fig. 2.9E). To determine if PU.1 interacts
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directly with the Nfkb1 promoter, ChIP analysis was performed. Reanalysis of published
ChIP-seq data (Heinz et al, 2010), and with our own ChIP-seq results (Fig. 2.9B),
revealed PU.1 interacting at the Nfkb1 promoter. Chromatin was prepared from freshly
isolated untreated and LPS stimulated B cells, and immunoprecipitated with anti-PU.1 or
control Abs. WT and PUB B cells were LPS stimulated for 16 h, as this time-point
provided increased p50 expression upon LPS exposure (Souvannavong et al, 2007).
Relative amounts of immunoprecipitated DNA was determined by qPCR from the Nfkb1
promoter region, the positive control Mef2c gene enhancer (DeKoter et al, 2010), and the
negative control Hprt. ChIP analysis confirmed less PU.1 occupancy at the Nfkb1
promoter of both freshly isolated untreated and LPS treated PUB B cells, whereas no
significant difference occurred at Hprt (Fig. 2.9F-G). Together, these data indicate that
both PU.1 and Spi-B directly activate Nfkb1 transcription in mice, suggesting that
reduced p50 expression in PUB B cells is the result of reduced PU.1 and Spi-B.
Enrichment of PU.1 and Spi-B binding did not occur most highly at the promoter
of Nkfb1. Several intronic regions of Nfkb1 contained even larger PU.1 and Spi-B
enrichment sites, suggesting that PU.1 or Spi-B may have higher affinity at enhancer
regulatory elements within the gene body which could act as enhancers (Fig. 2.10A).
Using the mouse intron as a template, an alignment was performed across multiple
species on the intron outlined in Fig. 2.10A. It was found that there was a high degree of
sequence similarity and a conserved ETS binding site within the intronic region (Fig.
2.10B). The conserved region containing the ETS binding site was cloned into a pGL3SV40 vector, which contained the SV40 promoter upstream of the luciferase gene. When
luciferase activity was measured in the pGL3-SV40 vector with the Nfkb1 intron inserted,
there was no increase in luciferase activity (Figure 2.10C). Therefore, the PU.1/Spi-B
binding region in intron 6-7 of Nfkb1 did not increase activation of the SV40 promoter.
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Figure 2.9. Nfkb1 is directly activated by PU.1 and Spi-B.
(A) PUB B cells express decreased p50 protein levels. Immunoblotting for p50 and actin was performed using enriched B cell lysates from WT and PUB mice. (B)
Chromatin immunoprecipitation-sequencing (ChIP-seq) analysis of PU.1 and Spi-B
interaction with the Nfkb1 gene. Murine WEHI-279 B cell lymphoma cells expressing
3XFLAG-tagged PU.1 (top) or Spi-B (bottom) were analyzed using anti-FLAG ChIPseq. Peaks located within and near the Nfkb1 gene are shown, and the dashed box
represents PU.1 and Spi-B binding at the Nfkb1 promoter. (C) Schematic showing
alignment of the annotated Nfkb1 promoter between multiple species. Grey text
represents conserved nucleotides, and boxes indicate predicted PU.1 binding sites with
similarity score and strand location (+/-) listed. Circled nucleotide represents known TSS
in the human Nfkb1 promoter. Dots represent TSS upstream or downstream of the
annotated sequence. (D) Luciferase reporter vector schematic with an arrow representing
the murine Nfkb1 TSS. The Nfkb1 promoter sequence was cloned by PCR and ligated
into pGL3-basic. Predicted ETS binding sites (wt) were mutated (mut) using site-directed
mutagenesis. (E) Mutated ETS binding sites reduced promoter activity in WEHI-279 B
cells. Cells were transfected with plasmids indicated on the x-axis. The y-axis indicates
fold-induction of luciferase activity relative to pGL3-basic. Luciferase activity was
normalized by transfection with Renilla luciferase expression vector. Data shows the
mean ±SEM (n=5). (F) Interaction of PU.1 with the Nfkb1 promoter is reduced in PUB B
cells. ChIP data shows % enrichment relative to input for PU.1 interaction with Nfkb1
and Hprt promoters, and is representative of three independent experiments. (G) Mean
fold enrichment of PU.1 binding in PUB B cells normalized to WT B cells for indicated
genes. Values of 1 (dashed line) indicate no difference in PU.1 binding between PUB and
WT B cells as compared to IgG. ChIP was performed on chromatin prepared from
untreated or LPS stimulated (16 h) freshly isolated splenic WT and PUB B cells using
anti-PU.1 and control IgG Abs. qPCR was used to measure the amount of
immunoprecipitated DNA after purification. Primers were designed to recognize
promoters of Nfkb1, Hprt, and Mef2c enhancer. Data shows the mean ±SEM of three
independent experiments. *p<0.05.
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Figure 2.10. Analysis of PU.1/Spi-B binding in the Nfkb1 intron.
(A) PU.1 and Spi-B bind to the intron of Nfkb1. ChIP-seq analysis was performed in
WEHI-279

3XFLAG-PU.1

and

WEHI-279

3XFLAG-Spi-B

cells,

and

immunoprecipitated with anti-FLAG antibody. The dashed box indicates the intron
region of Nfkb1 where PU.1 and Spi-B bind. (B) Alignment of the Nfkb1 intron across
multiple species where PU.1 and Spi-B bind. The region has a high degree of similarity
shown by the grey highlighted nucleotides. The sequence in the box is the ETS binding
site predicted by MatInspector. (C) The conserved intron sequence (400 bp) was cloned
into the pGL3-SV40 vector, and luciferase activity was measured in transfected WEHI279 cells.
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2.2.6 Forced expression of p50 or c-Rel in PUB B cells increases TLRmediated proliferation
PU.1 and Spi-B have been previously reported to directly regulate Rel
transcription (Hu et al, 2001). The Rel gene encodes for the NF-κB family member c-Rel,
which is required for survival and proliferation of B cells (Hu et al, 2001; Kontgen et al,
1995). Lower transcript levels of both Rel and Nfkb1 were detected in LPS stimulated
PUB B cells (Fig. 2.7F). Therefore it is conceivable that forced expression of c-Rel or
p50 could increase TLR-mediated proliferation in PUB B cells.
To assess whether PU.1 and Spi-B could directly bind near promoters of other
NF-κB family member, re-analysis of ChIP-seq data in WEHI-279 3XFLAG-PU.1 and
WEHI-279 3XFLAG-Spi-B cell was performed. It was confirmed that PU.1 and Spi-B
can bind proximal to the TSS of Nfkb2, Rela, Relb, and Rel (Figure 2.11). Therefore,
PU.1 and Spi-B may be involved with the transcriptional regulation of genes for all NFκB family members in B cells.
To determine if the PUB phenotype could be complemented by forced p50 or cRel expression, a retroviral vector was constructed encoding FLAG-tagged p50 (MIGP50) (Fig. 2.12A). A previously described retroviral vector containing c-Rel in the
MIGR1 vector was used to generate MIG-cRel virus (Sanjabi et al, 2005). FLAG-tagged
p50 protein was confirmed to be expressed in retroviral packaging cells transfected with
MIG-P50 using immunoblot (Fig. 2.12B). WT and PUB splenic B cells were enriched by
magnetic separation and stimulated with LPS and BAFF for 24 h to improve B cell
survival, followed by infection with MIG-P50 or MIGR1 virus as a control. Green
fluorescence, indicating B cell infection, was determined by flow cytometry (Fig. 2.12C).
Next, proliferation in response to LPS was assessed 24 hours post infection using MTT
assay (Fig. 2.12D). Despite low infection frequencies, both WT and PUB splenic B cells
infected with MIG-P50 virus had significantly increased proliferation compared to
MIGR1 infected cells (Fig. 2.12E). These data therefore suggest that forced p50
expression restores proliferation in PUB B cells.
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Figure 2.11. PU.1 and Spi-B bind near TSS of all NF-κB family members in WEHI-279
B cells.
FLAG-tagged PU.1 and Spi-B enrichment at all NF-κB family members is demonstrated
by enriched sequence tags. ChIP-seq was performed using anti-FLAG antibody on
WEHI-279 3XFLAG-PU.1 and WEHI-279 3XFLAG-Spi-B cells.
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For efficient retroviral integration, B cells needed to be in a state of division.
Since PUB B cells proliferated poorly in response to LPS alone (Fig. 2.6A, C), WT or
PUB B cells were stimulated with LPS, IL-2, IL-4, and IL-5 (IL-2+4+5), conditions
previously reported to improve survival (Grumont et al, 1998). LPS+IL-2+4+5 had
minimal effects on proliferation/survival in unstimulated or LPS stimulated WT B cells
measured using the MTT assay (Fig. 2.13A). However, the addition of IL-2+4+5
increased the frequency of PUB B cells that proliferated/survived compared to LPS alone
(Fig. 2.13A). To differentiate between a proliferation or survival effect of IL-2+4+5 on
PUB B cells, cells were stained with the proliferation dye eFluor® 450 prior to
stimulation, and the dilution of eFluor® 450 was assessed 72 h later by flow cytometry.
WT and PUB B cells responded minimally to IL-2+4+5 alone, based on the dilution of
eFluor® 450 (Fig. 2.13B). In WT B cells, addition of IL-2+4+5 did not affect LPSstimulated dilution of eFluor® 450 dye. In contrast, the frequency of cells that diluted
eFluor® 450 dye was dramatically increased in PUB B cells stimulated with LPS and IL2+4+5 compared to LPS alone (Fig. 2.13B). These results suggested that IL-2+4+5
increased survival in LPS stimulated PUB B cells.
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Figure 2.12. Forced expression of p50 significantly restores proliferation in PUB B cells.
(A) Schematic of the retroviral vector encoding FLAG-tagged Nfkb1 and GFP. (B) P50
expression in transfected Plat-E cells. Immunoblot analysis was performed using antiFLAG and anti--actin antibodies. Cell lysates were generated from Plat-E lysates
transfected with MIGR1 and MIG-P50 at high (44%) and low (18%) transfection
efficiencies. (C) Infection frequencies as determined by flow cytometry of green
fluorescence. WT splenic B cells were infected with MIGR1 (solid line, 18%) and MIGP50 (dashed line, 5%) virus. PUB splenic B cells were infected with MIGR1 (solid line,
16%) and MIG-P50 (dashed line, 4%) virus. Filled histograms indicated uninfected cells.
(D) Proliferation of WT and PUB B cells 24 h post-infection with MIGR1 and MIG-P50
virus. Cells were stimulated 24 h with LPS + BAFF prior to infection. Proliferation was
assessed via a MTT proliferation assay. Data shows the mean ±SD of duplicate
measurements, and is representative of 5 individual experiments. (E) Quantitation of five
individual experiments as performed in D. Data shows the mean ±SEM. Proliferation
index was calculated by normalizing OD570 of MIG-P50 infected cells to MIGR1 infected
cells in WT and PUB. *p<0.05.
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Next, to determine whether increased expression of p50 or c-Rel could increase
proliferation in infected WT or PUB cells, B cells were stimulated with LPS and IL2+4+5 for 24 h, then infected with MIGR1 (control), MIG-P50, or MIG-cRel retrovirus.
GFP expression was used as a marker for p50 or c-Rel infection, and a GFP+ population
was gated for proliferation analysis (Fig. 2.13C). WT and PUB B cells were infected with
MIGR1, MIG-P50, and MIG-cRel retroviruses with similar frequencies (Fig. 2.13D).
Next, proliferation was assessed for gated GFP+ p50-infected cells using eFluor® 450
staining and flow cytometry 48 h post infection. All cells that expressed GFP had also
diluted eFluor® 450, compared to GFP negative cells, which was expected since
retroviral infection requires cell division (Fig. 2.13E). For both WT and PUB GFP+ B
cells infected with MIG-P50, there was an increase in the frequency of cells that had
diluted eFluor® 450 compared to cells infected with MIGR1, suggesting one or more
extra rounds of cell division (Fig. 2.13E). This result was statistically significant based on
five independent experiments, and expressed either as a decrease in the eFluor® 450
mean fluorescence intensity (MFI) gated on GFP+ cells (Fig. 2.13F), or as the relative
frequency of cells diluting eFluor® 450 dye past the gate shown in Fig. 7G (Fig. 2.13G).
Finally, proliferation was assessed on MIG-c-Rel infected B cells (gated GFP+ cells) by
eFluor® 450 staining using flow cytometry 48 h post infection (Fig. 2.13H). Similar to
MIG-P50 infection, MIG-cRel infection in WT and PUB B cells resulted in a greater
degree of proliferation compared to MIGR1 infected cells (Fig. 2.13I). In addition, a
greater frequency of B cells proliferated when infected with MIG-cRel, compared to
MIGR1 infection (Fig. 2.13J). Overall, these results demonstrated that infection with
retroviral vectors encoding p50 or c-Rel expression was capable of increasing TLRmediated proliferation in WT and PUB B cells.
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Figure 2.13. Forced expression of p50 or c-Rel increases proliferation in PUB B cells.
(A) Proliferation of WT and PUB B cells in response to LPS and IL-2+4+5. Proliferation was
assessed 72 h post stimulation using an MTT proliferation assay. Data shows the mean ±SD
of triplicate measurements, and was representative of 2 individual experiments. (B) PUB B
cells have enhanced survival when stimulated with IL-2+4+5 in combination with LPS (grey
line), compared to LPS (dashed line) or IL-2+4+5 (dotted line) alone. Shaded histogram
represents untreated B cells. Proliferation was assessed by the dilution of the proliferation
dye eFluor® 450 using flow cytometry 72 h post stimulation. Data shown are representative
of three independent experiments. (C) MIGR1, MIG-P50, and MIG-cRel infected B cells
were identified by GFP expression (dashed gate) using flow cytometry. B cells were labeled
with proliferation dye eFluor® 450 and stimulated with LPS and IL-2+4+5 for 24 h prior to
infection with virus. (D) Similar infection frequencies between MIGR1, MIG-P50, and MIGcRel infected WT and PUB B cells based on gated population in C. (E) GFP+ B cells were
gated and assessed for dilution of eFluor® 450 to compare proliferation between MIG-P50
(dashed line) and MIGR1 (solid line) infected B cells. Shaded histogram represents
unstimulated control B cells. (F) WT and PUB B cells infected with MIG-P50 proliferate and
have increased dilution of eFluor® 450 compared to MIGR1-infected cells. Results are
expressed as the mean fluorescence intensity (MFI) of gated GFP + cells. (G) Increased
frequency of proliferating cells observed in MIG-P50 infected cells compared to MIGR1
infected cells. Results are expressed as the mean frequency of cells that diluted eFluor® 450
past the gate shown in panel E. (H) GFP+ B cells were gated and assessed for dilution of
eFluor® 450 to compare proliferation between MIG-c-Rel (dashed line) and MIGR1 (solid
line) infected B cells. Shaded histogram represents unstimulated control B cells. (I) WT and
PUB B cells infected with MIG-c-Rel proliferate more than MIGR1 infected cells, based on
dilution of eFluor® 450. (J) Increased frequency of proliferating cells observed in MIG-c-Rel
infected cells compared to MIGR1 infected cells. Results are expressed as the mean
frequency of cells that diluted eFluor® 450 past the gate shown in panel J. For F-G and I-J,
data is a quantitation of five individual experiments as performed in E and J respectively.
Data shows the mean ±SD. Normalized MFIs in F and I were calculated by dividing MFI
values of MIG-P50/MIG-cRel infected cells to MFI values of MIGR1 infected cells.
*p<0.05, **p<0.01, ***p<0.001.
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2.3

Discussion
The goal of this study was to understand how TLR-initiated signaling in B cells is

regulated. B cells from PUB mice proliferated poorly in response to TLR ligands. LPS
stimulated PUB B cells were activated and did not have increased apoptosis relative to
WT cells. The mechanism for the PUB phenotype revealed reduction in steady-state and
LPS stimulated levels of Nfkb1 transcripts, and accordingly lower p50 protein levels.
Mutation of two of the three ETS binding sites within the cloned Nfkb1 promoter reduced
its activation, suggesting that PU.1 and Spi-B regulate its transcription. PU.1 and Spi-B
interacted with the Nfkb1 promoter as shown by ChIP analysis, and PU.1 occupancy at
the Nfkb1 promoter was decreased in PUB B cells. Proliferation of PUB B cells was
increased upon retroviral complementation with p50. In summary, these results suggest
that activation of Nfkb1 by PU.1 and/or Spi-B promotes TLR-mediated splenic B cell
proliferation.
PU.1 and Spi-B are thought to be able to bind identical DNA binding sites (RayGallet et al, 1995). This idea was supported by our ChIP-seq results showing that PU.1
and Spi-B directly bind to the Nfkb1 promoter. Multiple TLR signaling genes have been
characterized as direct PU.1 targets, including Tlr4, Tlr9, Btk, and Rel (Hu et al, 2001;
Muller et al, 1996; Roger et al, 2005; Schroder et al, 2007). It is likely that altered protein
levels of these genes may contribute to the PUB B cell phenotype in addition to reduced
p50. Notably, transcript levels of Rel were reduced in PUB B cells stimulated with LPS.
The Rel gene encodes the NF-κB family member c-Rel, which is important for survival
and proliferation in B cells (Hu et al, 2001; Kontgen et al, 1995). Reduced c-Rel
expression impairs B cell proliferation, as Rel+/- and Rel-/- B cells proliferate poorly in
response to LPS or anti-IgM (Kontgen et al, 1995). Therefore, it is likely that impaired
proliferation of PUB B cells in response to LPS or anti-IgM is explained by reduced p50
and c-Rel (Hu et al, 2001). Proliferation in Rel-/- B cells is reported to be more impaired
than Nfkb1-/- B cells in response to either LPS or anti-IgM (Grumont et al, 1998; Kontgen
et al, 1995; Pohl et al, 2002). In addition, Rel+/- B cells have reduced proliferation in
response to LPS or anti-IgM compared to WT B cells, but there is no difference in levels
of proliferation between Nfkb1+/- and WT B cells for those same mitogens (Sha et al,
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1995; Snapper et al, 1996b). LPS stimulated Nfkb1-/- B cells fail to proliferate, anti-IgM
stimulation results in only a small reduction in proliferation, and anti-CD40/CD40L
stimulation results in normal proliferation (Garrett-Sinha et al, 1999; Sha et al, 1995;
Snapper et al, 1993). Deletion of both NF-κB1 and c-Rel (Nfkb1-/-Rel-/-) in B cells results
in a further impaired response to LPS or anti-IgM compared to Nfkb1-/- or Rel-/- B cells.
Future studies will need to be done to determine whether restoration of both p50 and cRel together can further improve proliferation responses in PUB B cells.
PUB B cells were unable to increase MHCII or CD40 expression upon LPS or
anti-IgM stimulation. The impairment of MHCII and CD40 upregulation upon anti-IgM
expression could be explained by increased apoptosis in PUB B cells. CD40 was
functional in PUB B cells since anti-CD40 stimulation appeared normal despite
decreased levels of CD40 on PUB B cells, furthermore, LPS+anti-CD40 stimulation was
able to rescue defective LPS-mediated proliferation. Failure to upregulate MHCII and
CD40 upon stimulation could result in decreased protein interaction necessary for TLR
activation, which could be a consequence of reduced p50 signaling. PUB B cells were
activated by LPS as measured by CD25 and CD69, but CD69 was not upregulated as
high as WT B cells. The Cd69 gene promoter has multiple PU.1 binding sites, and is
transcriptionally regulated by NF-κB complexes (Castellanos et al, 1997; Lopez-Cabrera
et al, 1995). Therefore, reduced MHCII, CD40, and CD69 upregulation upon LPS
stimulation may be a consequence of reduced p50 expression.
Although proliferation in PUB B cells was impaired upon TLR or IgM
stimulation alone, the combination of LPS+anti-IgM synergistically restored proliferation
and activation to WT levels in PUB B cells. The molecular basis of this observation is
unclear, but a comparable finding was made using Nfkb1-/-, Rel-/-, or Nfkb1-/-Rel-/- B cells,
where LPS synergized with anti-IgM when inducing proliferation (Pohl et al, 2002).
Furthermore, LPS and IL-2+4+5 were used to maximize cell survival to allow B cells
into early-log phase growth for viral infection. The combination of IL-2+4+5 was
previously reported to not induce proliferation on its own, but synergized with
proliferative responses to mitogens in WT, Rel-/-, and Nfkb1-/- B cells (Grumont et al,
1998). Similarly, PUB B cells did not proliferate highly in response to IL-2+4+5 alone,
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but the proliferation response was increased in response to LPS and IL-2+4+5. This
synergistic proliferation observed in PUB B cells is likely due to multiple or alternate
signaling pathways becoming activated, that are not regulated by PU.1 and Spi-B. For
example, LPS can also activate PI3K (Bone & Williams, 2001) or mitogen-activated
protein kinase (MAPK) pathways (Gerondakis et al, 2007). Therefore, there are likely
alternative pathways that can compensate in the event of having loss of PU.1 and Spi-B
function. Further analysis of PU.1 and Spi-B involvement on the activation of these
pathways through TLR ligands is required.
PUB mice have reduced frequencies of B cells with an increased ratio of MZ to
FO B cells, indicating PU.1 and Spi-B may regulate peripheral B cell differentiation
(DeKoter et al, 2010). FO and MZ B cell differentiation both require canonical NF-κB
signaling. Weak BCR signaling promotes MZ B cell development, whereas strong BCR
signaling drives FO B cell development (Pillai & Cariappa, 2009). Nfkb1-/- mice have MZ
B cells, although in decreased numbers (Cariappa et al, 2000), and MZ B cells
accumulate over time in spleens of these mice (Ferguson & Corley, 2005). Therefore,
increased MZ B cell and decreased FO B cell frequencies in PUB spleens might be
caused by a combination of altered NF-κB signaling, weakened BCR signaling, and
increased apoptosis upon BCR stimulation.
In summary, our experiments establish the importance of PU.1 and Spi-B for
innate immune responses in B cells. Decreased p50 and reduced Nfkb1 gene activation in
PUB mice is associated with poor TLR-mediated B cell proliferation. Understanding
TLR regulation in B cells has implications for generation of antibody responses, since
effective thymus-independent responses and production of antibodies in vaccinations are
dependent on direct TLR triggering on B cells (Kasturi et al, 2011). Further analysis of
mice lacking Spi-B and reduced PU.1 is expected to provide additional insight into other
genes involved in TLR signaling and antibody forming responses.
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2.4 Materials and Methods
2.4.1 Generation and breeding of mice
Mice were housed at Western University’s Health Sciences animal facility (London,
Ontario, Canada) and monitored under an approved animal use subcommittee protocol in
accord with Western University Council on Animal Care. C57BL/6 (WT) mice were
purchased from Charles River Laboratories (Pointe-Claire, Quebec, Canada). PUB mice
were generated by mating male and female PUB mice, and genotyping was performed by
PCR as previously described (Garrett-Sinha et al, 1999; Su et al, 1997). Experiments
were performed on mice aged 6-16 wks.

2.4.2 B cell enrichment and proliferation analysis
RBCs were removed from spleen cell suspensions by hypotonic lysis with ammonium
chloride solution. B cells were enriched by negative selection using biotin-conjugated
anti-CD43 (S7) Ab, streptavidin (SA) microbeads, LD depletion columns, and a
VarioMACS™ separation unit (Miltenyi Biotec, Germany). Enrichment of B cells
provided a >95% pure B cell population as determined by flow cytometry. B cells
(2x105/well) were plated in 96-well flat bottom plates and stimulated with LPS (10
μg/mL, List Biological Laboratories), anti-IgM Ab (50 μg/mL, affinity pure F(ab’)2
fragment, goat anti-mouse IgM, μ chain specific; Jackson ImmunoResearch
Laboratories), Pam3CSK4 (1 μg/mL), HKLM (108 cells/mL), Poly(I:C) LMW or HMW
(10 μg/mL), ST-FLA (10 μg/mL). FSL1 (1 μg/mL), ODN1826 (5 uM, InvivoGen), BAFF
(100 ng/mL, Peprotech, New Jersey, USA), or LEAFTM purified anti-mouse CD40 (10
μg/mL; IC10, BioLegend) in complete DMEM. Proliferation was assessed after 72 h
incubation at 37°C with a TACS® MTT Cell Proliferation assay (Trevigen) used
according to the manufacturer’s instructions. For [3H]-thymidine incorporation assays,
[3H]-thymidine (1 mCi/mL/well) was added after 72 h stimulation, followed by
scintillation counting 18 h later.
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2.4.3 Flow cytometry
Antibodies purchased from eBioscience (San Diego, CA) or BioLegend (San Diego, CA)
included allophycocyanin (APC)-conjugated anti-B220 (RA3-6B2), anti-MHCII [I-A/I-E
(M5.144.15.2)], anti-CD40 (3/23), BAFF-R (eBio7H22-E16), phycoerythrin (PE)conjugated anti-CD19 (1D3), IgG Isotype Control (eBio299Arm), anti-CD69 (H1.2F3),
anti-CD281/TLR1 (eBioTR23), anti-CD282/TLR2 (T2.5), IgG2a κ Isotype Control
(eBM2a), anti-CD14 (Sa14-2), anti-CD180/RP105 (RP/14), fluorescein isothiocyanate
(FITC)-conjugated anti-CD21/CD35 (eBio8D9), Alexa Fluor®488-conjugated anti-CD1d
(1B1), Biotin-conjugated anti-CD25 (7D4), anti-CD5 (53-7.3), or SA conjugated-PE. For
proliferation analyses, cells were stained with the proliferation dye eFluor® 450
(eBioscience). Antibody-stained cell analysis and sorting was performed using a
FACSCalibur and FACSAriaIII system respectively (BD Biosciences, San Jose, CA).
Sorted cells were determined to be >98% purity. Data analysis was performed using
FlowJo software (FlowJo LLC, Ashland, OR).

2.4.4 Reverse transcription-quantitative PCR
RNA was isolated using Trizol® reagent (Life Technologies Inc. Burlington ON). cDNA
was synthesized using an iScript cDNA Synthesis Kit (Bio-Rad, Mississauga, Ontario,
Canada), and qPCR was performed with a Rotor-Gene 6000 instrument (Corbett Life
Sciences, Valencia, CA). Relative mRNA transcript levels were normalized to GAPDH
or β2m and compared between samples using the comparative threshold cycle method.
Calculations were performed using REST© 2009 software (Pfaffl et al, 2002). Primer
sequences are listed in Table 2.1.

2.4.5 Immunoblot analysis
Lysates were prepared using the Laemelli method and applied to 8%-10% SDS
polyacrylamide gels for electrophoresis. Proteins were transferred to nitrocellulose
membranes using a Trans-Blot Semi-Dry system (Bio-Rad), and membranes were
blocked for 1 h in 5% milk in TBST. Membranes were probed with polyclonal antiMyD88 (eBioscience), anti-Btk (B3H5, Cell Signaling Technology, Whitby ON), anti-
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Nfkb1 (Poly6197, BioLegend), or anti-β-Actin (I-19, Santa Cruz Biotechnology) Ab, and
diluted to concentrations recommended by their manufacturers in 1% milk/TBST
overnight at 4°C. A secondary horseradish peroxidase-conjugated anti-goat or anti-mouse
Ab was incubated in 1% milk/TBST. Membranes were washed and visualized with
SuperSignal West Pico reagent (Thermo-Fisher Scientific, Waltham MA).

2.4.6 Bioinformatic analysis
A TSS was previously described for the human NFKB1 promoter (Cogswell et al, 1993).
DNA sequences from human, mouse, rat, macaque, dog, cow, and Tasmanian devil were
obtained from the Ensembl database and aligned using MacVector (Accelrys, San Diego,
CA). Predicted transcription factor binding sites were analyzed using MatInspector
(Genomatix, Ann Arbor, MI), with scores >0.9 selected for further analysis.

2.4.7 Plasmids and cloning
The Nfkb1 promoter was amplified from C57BL/6 genomic DNA by PCR using LATAQ (TaKaRa Clontech Laboratories Inc, Mountain View, CA), purified, and cloned
into pSC-A vector using a PCR cloning kit (Agilent Technologies, La Jolla, CA). A
468bp Nfkb1 promoter fragment was PCR amplified using a forward primer containing a
HindIII site and subcloned. The promoter was HindIII digested from pSC-A and ligated
into the HindIII site of the pGL3-basic (Promega) luciferase reporter vector. Predicted
ETS binding sites were mutated using the QuickChange lightning site-directed
mutagenesis kit according to the manufacturer’s instructions (Agilent Technologies). The
murine stem cell virus-internal ribosomal entry site-green fluorescent protein (MSCVIRES-EGFP; MIGR1) retroviral vector has been described (Pear et al, 1998). MSCVP50-IRES-EGFP (MIG-P50) was generated by cloning p50-FLAG from the p50 cFlag
pcDNA3 vector purchased from Addgene (Plasmid 20018; Cambridge, MA) by XhoI and
EcoRI digestion. P50-FLAG was cloned into the psC-A vector, excised with EcoRI, and
ligated into the MIGR1 vector. MIG-cRel (Plasmid 26984) was obtained from Addgene
(Cambridge, MA) (Sanjabi et al, 2005). All constructs were verified by DNA sequencing.
Transfection-quality plasmid DNA was prepared by growth in DH5α bacteria and
purified with plasmid maxi prep kit (Qiagen). All restriction enzymes were purchased
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from New England Biolabs (Ipswich, MA). Primer sequences used for cloning are listed
in Table 2.1.

2.4.8 Generation of retrovirus
MIG-P50, MIG-cRel, and MIGR1 retroviral vectors were generated by transient
transfection using PEIproTM (Polyplus-transfection, Illkirch, France) into Platinum-E
(Plat-E) packaging cells (Morita et al, 2000). Plat-E cells were maintained in complete
DMEM (1.5 g/mL glucose) with blasticidin (10 μg/mL) and puromycin (1 μg/mL). Cells
were passaged in antibiotic free media 72 h prior to transfection, then plated at 3x10 6
cells per 100mm culture dish. A 2:1 PEI/DNA (20 µL PEIpro TM and 10 µg plasmid
DNA) ratio was used for transfections, with a final working concentration for PEI at 0.5
µg/mL. Transfections were performed using DMEM without FBS or antibiotics for 4 h at
37°C. Cells were washed with fresh complete DMEM following transfection and
incubated for 48h at 37°C. Virus-containing supernatants were collected following 48 h,
and virus production was confirmed by green fluorescence and FLAG-tagged protein
using flow cytometry and immunoblot respectively.

2.4.9 Retroviral infection of primary B cells and proliferation analysis
To assess proliferation in total B cells, B cells were isolated from spleens by
magnetic enrichment as mentioned in 2.4.2 and stimulated for 24 h with BAFF (100
ng/mL) and LPS (10 μg/mL). Next, cells were infected by spinoculation with virus by
centrifugation at 800 x g for 2 h at 30°C in the presence of polybrene at a final
concentration of 4 μg/mL. After centrifugation, cells were cultured for another 24 h.
Infection frequencies were detected by flow cytometric analysis for green fluorescence
expression. Proliferation of total cells was assessed by MTT proliferation assay.
To assess proliferation specifically in infected B cells, B cells were isolated from
spleens by magnetic enrichment as mentioned in 2.4.2 and stained with the cell
proliferation dye eFluor® 450 (10 µM; eBioscience). B cells were stimulated for 24 h
with LPS, IL-2 (10 ng/mL), IL-4 (10 ng/mL), and IL-5 (10 ng/mL). Next, cells were
infected by spinoculation with virus by centrifugation at 800 x g for 2 h at 30°C in
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Table 2.1. Forward and reverse primers used for RT-qPCR analysis, cloning, and site
directed mutagenesis.
DNA Sequence (5’ -> 3’)

Primer Name
B2m fwd

5’-TGG CTC ACA CTG AAT TCA CCC CCA-3’

rev

5’-TCT CGA TCC CAG TAG ACG GTC TTG-3’

Cd14 fwd
rev

5’-CCC AAG CAC ACT CGC TCA ACT TT-3’

5’-ACC CAA TTT ATG ACA ACC GTG CCC-3’

rev

5’-ACC TCT GGC TTC CCA GTC ATT CAA-3’

rev

5’-GAA CAT CAT CCC TGC ATC CA-3’

5’-GGC CCA CCT AGT CAG ATA AGA GT-3’

rev

5’-GAA AGC AGT GAG GTA AGC CCA AC-3’

Myd88 fwd

5’-TAA GTT GTG TGT GTC CGA CCG TGA-3’

rev

5’-ATC AGT CGC TTC TGT TGG ACA CCT-3’

Traf6 fwd

5’-TTT ACG GGA AGC AGT GCA AAC ACC-3’

rev

5’-ATT TGG GCA CTT TAC CGT CAG GGA-3’

Irak3 fwd

5’-AGA GCT GGC TGC ATA TTT CAC GGA-3’

rev

5’-GGG TTG TGC CAT TTG TGC ACT GTA-3’

rev
Mef2c ChIP fwd
rev

5’-ACG GGC TTC GGC AAG GCT A-3’

5’-GAA GGA AGC ACC TTT ACA CC-3’

rev

5’-TCC CTC GAA AGA GAA TGG TAT TGA-3’

Nfkb1 ChIP fwd

78 bp

193 bp

192 bp

181 bp

107 bp

192 bp

125 bp

5’-TTC AGC AAA TCC CTC CTA GT-3’
5’-TAG AGT TGC CGA AGC GTA AGG AAG-3’

rev

170 bp

5’-ATC CAG CAG TAG TTG AGG TTC ACG-3’

Md2 fwd

Nfkb1 fwd

106 bp

5’-CCA GTG AGC TTC CCG TTC A-3’

Hprt ChIP fwd

Irak4 fwd

100 bp

5’-ATC AGT CCT CTC TCG CCC AAT-3’

Rel fwd

Gapdh fwd

Product size

5’-GCT GAG TCC TGC TCC TTC TAA A-3’

116 bp

104 bp

5’-CCT CTG TGT AGC CCA TCT GTT GC-3’
5’-TCC GTC TGT CTG CTC TCT-3’

123 bp
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Rev
Nfkb2 fwd
rev
Rela fwd
rev
Relb fwd

5’-GGT GGC GAA ACC TCC TC-3’
5’-CGG TGG AGA CGA AGT TTA TTT GCT C-3’
5’-ATC TTG TGA TAG GGC GGT GT-3’
5’-CGG GAT GGC TAC TAT GAG GCT GAC-3’

5’-ACA CCC ACA TAG CCT CGT-3’
5’-ATT TCC TTC TTC CTA ACA CAC TGGA-3’

Tlr1 fwd

5’-ACA GTC AGC CTC AAG CAT TTG GAC-3’

5’-ATG CTT CGT TGT TCC CTG TGT TGC-3’

rev

5’-AAA GTG GTT GTC GCC TGC TTC CA-3’
5’-ACT GTT CTT CTC CTG CCT GA-3’

rev

5’-GGG ACT TTG CTG AGT TTC TGA TCC-3’

Tlr7 fwd

5’-GTG ATG CTG TGT GGT TTG TCT GGT-3’

rev

5’-CAC TTT GAC CTT TGT GTG CTC CTG-3’

Tlr8 fwd

5’-TGG TTA TGT TGG CTG CTC TGG TTC-3’

rev

5’-TTG GGA TGT GGA TGA AGT CCT GTA GC-3’

Tlr9 fwd

5’-TGG ACG GGA ACT GCT ACT ACA AGA AC-3’

rev

5’-CTT CAG AGA CAG ATG GGT GAG ATT GC-3’

Tollip fwd
rev
Nfkb1 Promoter fwd
rev
Nfkb1 Sublone w/ HindIII
fwd
Rev

126 bp

117 bp

5’-TAC CCG AGA ACC GCT CAA CC-3’

Tlr2 fwd

Tlr4 fwd

134 bp

5’-GGG TTA TTG TTG GTC TGG ATT CGC-3’

rev

rev

169 bp

5’-GGT CGC CTC AGC ATC ACT-3’

125 bp

102 bp

108 bp

110 bp

101 bp

104 bp

5’-TCA TAA ACA GCA TAG CCC AGA CGCA-3’
5’-CCC AAA GAA TAA AGA CGC TCA AAT GC-3’

1745 bp

5’-TCA GAA GAC CGA AGG AAG CCT ACA-3’
5’-CAA GCT TAC CTC CCG CCC CC-3’

468 bp

5’-CCT GGA GAT GCG GCG CGG-3’

pGL3-Nfkb1 Mutation

5’-TCT CGA CGT CAG TGG GAA TGT CCA GC-3’

pGL3-Nfkb1 Mutation anti

5’-TCG CTC ACT CTC TCA CGT CCT GGC TGG-3’

N/A
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the presence of polybrene at a final concentration of 4 μg/mL. Infection frequencies were
detected by flow cytometric analysis for green fluorescence expression. Proliferation of
infected cells was assessed by the dilution of eFluor® 450 using flow cytometry 48h post
infection.

2.4.10 Transient transfection by electroporation
WEHI-279 cells in mid to early log phase growth were washed three times with serumfree DMEM (4.5g/L, Lonza). Cells were incubated for 10 min at room temperature with
10 μg of each luciferase reporter plasmid and 1 μg of pRL-TK (Promega). Cell-DNA
mixtures were electroporated at 220 V and 950 mF using 4-mm gap cuvettes and a
GenePulser II with Capacitance Extender (Bio-Rad), incubated at room temperature for
10 min, then transferred to 6-well culture plates in complete DMEM and incubated at
37°C for 24 h. A Dual-Luciferase Reporter Assay System (Promega) was performed on
cell lysates. Light production was measured using a Lumat LB 9507 tube luminometer
(Berthold Technologies, Oak Ridge, TN).

2.4.11 ChIP-Seq Analysis
ChIP-seq experiments were performed using mouse WEHI-279 cells. Cells were spininfected with a MIGR1 vector for expression of 3XFLAG-PU.1 or 3XFLAG-Spi-B.
Immunoprecipitation was performed using anti-FLAG microbeads (M2, Sigma-Aldrich,
St. Louis, MO). Purified chromatin was sequenced using an Illumina HiSeq instrument.
Peak finding and data analysis was performed using Galaxy Suite (Blankenberg et al,
2010; Giardine et al, 2005; Goecks et al, 2010). Reads were aligned to the reference
genome (NCBI37/mm9), using BOWTIE (Langmead et al, 2009). Peaks were called
using MACS version 1.0.1 (Zhang et al, 2008) with default parameters, a P-value cutoff
for peak detection of 1e-05 and an effective genome size of 2.7e+9 bp. Functional
analysis of cis-regulatory regions bound by PU.1 and Spi-B were identified using
GREAT V.2.0.2 (McLean et al, 2010). Data are available from the Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo) under accession number GSE58128.
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2.4.12 ChIP experiments
Chromatin was prepared from enriched B cells as previously described (DeKoter et al,
2010). In brief, cells were cross-linked and lysed followed by sonication. Sonicated
chromatin was incubated overnight at 4°C with anti-PU.1 or control mouse anti-IgG Ab
(Santa Cruz Biotechnology) conjugated to protein G DynaBeads (Invitrogen, Burlington,
Ontario, Canada). Magnetic bead complexes were enriched using a MagneSphere®
Technology Magnetic Separation Stand (Promega) and washed. Immunocomplexes were
eluted and cross-linked chromatin was reversed overnight at 65°C. DNA was purified
using a QIAquick PCR purification kit (Qiagen). Enrichment was measured using qPCR
of immunoprecipitated DNA using primers indicated in supplemental Table 2.1.

2.4.13 ELISA analysis
Serum

was

collected

and

quantified

using

a

Quantikine

ELISA

Mouse

BAFF/BLyS/TNFSF13B Immunoassay kit (R&D Systems, Minneapolis, MN) according
to the manufacturer’s instructions. Plates were analyzed using an EON Microplate
Spectrophotometer with Gen5 software (BioTek, Winooski, VT).

2.4.14 Statistical analysis
Statistical significance was determined using Student’s t test unless otherwise indicated.
P values ≤0.05 were considered significant. For all figures, *P ≤0.05, **P ≤0.01, and
***≤P 0.001. Statistical analysis was performed using Prism 5.0 (Graph-Pad Software).
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Chapter 3

3

Identification of a negative regulatory role for Spi-C in the
murine B cell lineage
Spi-C is an E26 transformation-specific family (ETS) transcription factor that is

most highly related to PU.1 and Spi-B. Spi-C (encoded by Spic) is expressed in
developing B cells, but its function in B cell development and function is not well
characterized. To determine if Spi-C functions as a negative regulator of Spi-B (encoded
by Spib), mice were generated that were germline knockout for Spib and heterozygous for
Spic (Spib-/-Spic+/-). Interestingly, loss of one allele of Spic substantially rescued B cell
frequencies and absolute numbers in the spleens of Spib-/- mice. Spib-/-Spic+/- mice had
restored proliferation compared to Spib-/- mice in response to anti-IgM or LPS
stimulation. Spib-/- B cells had reduced expression of genes required for B cell receptor
signalling including Nfkb1 encoding P50, and Nfkb1 transcript levels were restored by
loss of one allele of Spic. Finally, Spi-B was shown to directly activate the Nfkb1 gene
while Spi-C was shown to repress this gene. These results indicate a novel role for Spi-C
as a negative regulator of B cell development and function.

3.1 Introduction
B cell development occurs in the bone marrow of mammals, where committed
progenitor B (pro-B) cells are generated from lymphoid progenitor cells. Pro-B cells
develop into mature B cells through a series of defined stages marked by rearrangement
of immunoglobulin heavy chain (IgH) and immunoglobulin light chain genes. Immature
B cells leaving the bone marrow are termed transitional-1 (T1) B cells, which migrate to
the spleen and differentiate into T2 B cells (Pillai & Cariappa, 2009). T2 B cells can
mature into either follicular (FO) or marginal zone (MZ) B cells that go on to participate
in antibody formation and immune regulation (Pillai & Cariappa, 2009).
Transcription factors function as either activators or repressors of gene expression
to govern B cell development. E26-transformation-specific (ETS) transcription factors
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PU.1 (encoded by Spi1) and Spi-B (encoded by Spib) function as transcriptional
activators during B cell development. PU.1 is required to generate B cell progenitors, as
Spi1-/- mice have a profound block in B cell development (Houston et al, 2007; Scott et
al, 1994). Spib-/- mice have reduced numbers of B cells that are defective in BCR
signalling and are unable to sustain antibody responses to T-dependent antigens (GarrettSinha et al, 1999; Su et al, 1997). PU.1 and Spi-B activate transcription by interacting
with the consensus core motif 5’-GGAA-3’ at specific sites within the genome (RayGallet et al, 1995). Due to the similarities in DNA binding specificities and overlapping
expression patterns, many gene targets are functionally redundant between PU.1 and SpiB, although there are also exclusive roles for each (DeKoter et al, 2010; Sokalski et al,
2011; Su et al, 1997).
Transcriptional networks that control B cell differentiation include both
transcriptional activators and repressors (Rothenberg, 2014). Interestingly, few published
examples of negative regulators of ETS transcription factor function exist. Spi-C is an
ETS transcription factor that is a potential negative regulator. Spi-C was originally
described as a PU.1-related protein containing an N-terminal acid activation domain
(Bemark et al, 1999; Carlsson et al, 2003; Carlsson et al, 2006). Ectopic overexpression
of Spi-C in either cultured pro-B cells using a retroviral vector (Schweitzer et al, 2006) or
in mice using a B cell specific transgene (Eμ-Spi-C) (Zhu et al, 2008) has suggested that
Spi-C functions as a negative regulator by opposing PU.1 activity. Transgenic Spi-C
expression under the control of the B cell-specific IgH intronic enhancer resulted in
reduced absolute numbers of T1, T2, MZ, and FO B cells in Eμ-Spi-C mice compared to
WT mice (Zhu et al, 2008). Recently a Spic knockout mouse was generated, allowing for
Spi-C loss-of-function analysis (Kohyama et al, 2009). Spi-C was revealed to be essential
for generating red pulp macrophages in the spleen and is inducible by Heme (Haldar et al,
2014). Spi-C is upregulated in B cells lacking the transcriptional repressors Bach1/Bach2,
and results in altered gene expression patterns in B cells (Itoh-Nakadai et al, 2014).
Therefore, Spi-C may have a regulatory role in B cells for development and function.
The goal of this study was to determine if Spi-C plays a negative regulatory role
in B cell development and function. A loss-of-function approach was used by crossing a
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Spic null allele onto a Spib knockout background (Spib-/-Spic+/- mice). The effect of Spic
heterozygosity in Spib-/- mice might 1) have no effect on the phenotype, 2) further impair
B cell development, or 3) rescue the Spib-/- phenotype. It was observed that Spic
heterozygosity substantially rescued both development and function of B cells in Spib-/mice. Taken together, our results identify a negative regulatory role for Spi-C in B cells.

3.2 Results
3.2.1 Restored splenic B cells numbers in Spib-/-Spic+/- mice compared to
Spib-/- Spic+/+ mice
To determine roles of Spi-C in B cell development, mice homozygous for
germline null alleles of Spib (Su et al, 1997) and heterozygous Spic (Kohyama et al,
2009) were mated. Spib-/-Spic+/- mice were generated near Mendelian ratios (Table 3.1)
and were healthy and fertile. However, few Spib-/-Spic-/- mice were generated (Table 3.1).
Therefore, these studies focussed on analysis of Spib-/-Spic+/+ and Spib-/-Spic+/- mice.
To determine that the haploid state of Spi-C is insufficient in Spib-/-Spic+/- mice,
immunoblot analysis was performed on WT, Spib-/-, and Spib-/-Spic+/- spleen lysates to
detect protein levels of Spi-C. A reduction in Spi-C was measured in Spib-/-Spic+/- spleen
lysates compared to WT or Spib-/- (Fig. 3.1A). As previously noted, Spib-/- mice had
reduced total numbers of splenocytes compared to WT (Fig. 3.1B). However, total
numbers of splenocytes were substantially rescued in Spib-/-Spic+/- mice compared to
Spib-/- mice (Fig. 1B). In order to assess the population of mature B cells, frequencies of
B220+CD93- cells were determined using flow cytometry (Fig. 3.1C). Spib-/- spleens
contained decreased frequencies of mature B cells and decreased absolute numbers of
mature B cells. In contrast, Spib-/-Spic+/- spleens had substantially rescued frequencies and
absolute numbers of mature B cells compared to Spib-/- spleens (Fig. 3.1D). Overall, these
results showed that knocking out one allele of Spic on a Spib-/- background rescued
absolute number of mature B cells in Spib-/- spleens. These results suggest that Spi-C
levels are involved in regulating B cell differentiation.
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Table 3.1. Expected and actual frequencies of mouse genotypes from offspring generated
by mating male and female Spib-/-Spic+/-.
Genotype

Number of mice

Expected

Actual Frequencyb

produced

Frequencya (%)

(%)

Spib-/-Spic+/+

101

25

36.5

Spib-/-Spic+/-

174

50

62.8

Spib-/-Spic-/-

2

25

0.7

aExpected

bActual

frequencies are based on Mendelian ratios.

frequencies are based on the genotyping of 277 pups.
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3.2.2 Rescued absolute number of FO B cells in Spib-/-Spic+/- spleens
compared to Spib-/- spleens
Spib-/- mice were reported to have reduced frequencies of FO B cells (DeKoter et
al, 2010). To determine whether mature MZ and FO B cell populations were restored in
Spib-/-Spic+/- spleens, flow cytometry was performed on splenocytes from WT, Spib-/- and
Spib-/-Spic+/- mice. Mature B cells were gated on B220+CD93-, followed by analysis of
CD21 and IgM surface expression to identify FO (CD21lowIgMint) and MZ (CD21hiIgMhi)
B cells (Fig. 3.1E). Absolute numbers of MZ B cells were unaffected by either reduced
Spi-B or Spi-C expression. However, FO B cells were decreased in both frequency and
absolute number in Spib-/- spleens compared to WT (Fig. 3.1F). Spib-/- Spic+/- spleens
contained restored absolute numbers of FO B cells compared to Spib-/- spleens (Fig.
3.1F). Next, MZ and FO B cell populations were quantified by CD23 and IgM surface
expression (Fig. 3.1G). Absolute numbers of MZ B cells (IgMhiCD23-/low) were
unchanged between WT, Spib-/- and Spib-/-Spic+/- spleens. However, frequencies of FO B
cells (IgMintCD23+) were reduced in Spib-/- spleens, and this reduction was rescued in
Spib-/-Spic+/- spleens (Fig. 3.1H). Taken together, these results suggest that the rescue in
absolute numbers of mature B cells in Spib-/- Spic+/- spleens was primarily a result of
increased FO B cells.
It has been previously reported that there is differential Spi-C transcript
expression between B-1a, B-1b, and splenic B2 cells (Kretschmer et al, 2003). To assess
if there were any differences in B-1 cell populations in the peritoneal cavity of Spib-/Spic+/-, peritoneal fluid isolated from WT, Spib-/- and Spib-/-Spic+/- mice were analyzed by
flow cytometry (Figure 3.2A). No differences in CD19+CD5+ (B-1a) cell frequency were
detected between WT, Spib-/- and Spib-/-Spic+/- mice (Figure 3.2B). Spib-/-Spic+/- B-1a
cells from the peritoneal cavity expressed elevated CD19 levels compared to WT mice
(Figure 3.2C). Therefore, loss of Spi-C expression in Spib-/-Spic+/- mice altered CD19
expression in B-1a cells.
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Figure 3.1. Spi-C heterozygosity rescues absolute numbers of B cells in the spleens of
Spib-/- mice.
(A) Spi-C protein expression measured in WT, Spib-/-, and Spib-/-Spic+/- spleen lysates.
Immunoblot was performed using anti-Spi-C antibody and anti-β-Actin as a loading
control. Data shown is a representative of 3 individual experiments. (B) Cell counts based
on total cells isolated from the spleens of WT, Spib-/-, and Spib-/-Spic+/- mice. (C) Mature
B cells were quantified by flow cytometry based on B220 and CD93. The dashed box
represents the mature B cell population. (D) Quantitation of the frequency and absolute
number of B220+CD93- splenocytes identified in WT, Spib-/-, and Spib-/-Spic+/- mice. (E)
Mature FO and MZ B cell populations were quantified based on CD21 and IgM surface
expression. (F) Quantitation of the frequency and absolute number of MZ (CD21hiIgMhi)
and FO (CD21lowIgMint) mature B cells (B220+CD93-) in the spleen. (G) Mature FO and
MZ B cell populations were quantified based on CD23 and IgM surface expression. Cells
were isolated from WT, Spib-/-, and Spib-/-Spic+/- spleens and analyzed by flow cytometry.
(H) Quantitation of the frequency and absolute number of MZ (CD23lowIgMhi) and FO
(CD23hiIgMint) mature B cells (B220+CD93-) in the spleen. For B, and D, data is shown
as mean and SD of 14 individual mice. For F and H, data is shown as mean and SD of 9
individual mice. *p<0.05; **p<0.01; ***p<0.001.

93

94

Figure 3.2. B-1a cells from the peritoneal cavity of Spib-/-Spic+/- mice express elevated
CD19 levels.
(A) Comparison of the frequency of CD19+CD5+ cells in the peritoneal cavity of WT,
Spib-/-, and Spib-/-Spic+/- mice. Dashed box represents the B-1a population. Data is a
representative of three independent experiments. (B) Quantitation of A showing the mean
frequency of B-1a cells as a percentage of total CD19+ cells. (C) Levels of CD19
determined by the mean fluorescence intensity (MFI). For B and C, data shows mean and
SD of three individual mice.
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3.2.3 Increased transitional B cells in Spib-/-Spic+/- spleens compared to
Spib-/- spleens
Since Spib-/- Spic+/- spleens had increased numbers of FO B cells compared to
Spib-/-, it was hypothesized that there were increased immature B cells developing in the
bone marrow of these mice. To test this, flow cytometry analysis was performed using
the “Hardy” staining scheme for bone marrow cells (Hardy et al, 1991) (Fig. 3.3A).
Although Spib-/- mice had increased fraction D and reduced fraction F populations
compared to WT B cells, no significant differences in frequencies of fractions A through
F were observed between Spib-/- and Spib-/- Spic+/- mice (Fig. 3.3B-C). These results
suggested that restored FO B cell numbers were not due to an increase in frequency of B
cell progenitors derived from the bone marrow.
To assess whether rates of apoptosis were altered in Spib-/- Spic+/- B cells, flow
cytometry was performed on WT, Spib-/- and Spib-/- Spic+/- splenocytes. Cells were gated
into T1, T2, MZ, and FO B cell populations based on B220, CD93, IgM, and CD23
staining, and apoptotic cells were gated for Annexin V+7-AAD- (Fig. 3.4A). No
differences were detected in apoptotic frequency in either total B cells (Fig. 3.4B) or
gated T1, T2, MZ, or FO B cells (Fig. 3.3C) between WT, Spib-/- and Spib-/- Spic+/- mice.
These results suggest that reduced Spi-C expression does not significantly alter steadystate levels of apoptosis in Spib-/- mice.
To determine the source of rescued numbers of FO B cells in Spib-/-Spic+/- spleens
compared to Spib-/-, immature transitional B cell populations were examined. Immature B
cells were gated on expression of both B220 and CD93 (Fig. 3.5A). There were increased
frequencies of B220+CD93+ immature B cells in both Spib-/- and Spib-/-Spic+/- spleens
compared to WT, but no significant difference in frequency of these cells between Spib-/and Spib-/-Spic+/- spleens. In contrast, absolute numbers of immature B cells were nearly
doubled in Spib-/-Spic+/- spleens compared to WT or Spib-/- spleens (Fig. 3.5B). To
determine which immature B cell subset was accountable for overall increased numbers,
analysis of transitional T1, T2, and T3 B cell populations was performed by gating
immature B220+CD93+ B cells for differential expression of IgM and CD23 (Fig. 3.5C).
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Figure 3.3. No differences in B cell composition between Spib-/-, and Spib-/-Spic+/- mice
in the bone marrow.
(A) Bone marrow analysis was performed on WT, Spib-/-, and Spib-/-Spic+/- mice. Cells
were analyzed by flow cytometry and gated using the Hardy scheme for quantifying B
cell populations during development. Data shown is a representative of 8 individual mice.
(B) Quantitation of individual fractions A-F located in the bone marrow calculated as a
percentage of total B220+ cells in the bone marrow. (C) Quantitation of individual
fractions A-F located in the bone marrow calculated as a percentage of total cells in the
bone marrow. Fractions were gated using the Hardy scheme. For B-C, data is shown as
mean and SD of 8 individual mice. **p<0.01; ***p<0.001.
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Figure 3.4. No differences in the frequency of apoptosis between WT, Spib-/-, and Spib-/Spic+/- B cells.
(A) Rates of apoptosis were analyzed by flow cytometry using Annexin V and 7-AAD
staining on WT, Spib-/-, and Spib-/-Spic+/- splenocytes. Prior to Ab staining, spleens were
enriched for B cells by magnetic CD43+ cell depletion. Cells were stained for B220,
CD93, IgM, CD23, Annexin V, and 7-AAD to allow for gating on transitional T1, T2,
and mature FO and MZ B cell populations. Apoptotic frequencies (Annexin V+ 7-AAD-;
red box) were assessed for each gated subset. (B) Quantitation of the frequency of
apoptosis in total B cells. (C) Quantitation of apoptotic transitional T1, T2, FO and MZ B
cells. For B-C, data is shown as mean and SD of 4 individual mice.
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No differences in T3 B cells were observed between WT, Spib-/- and Spib-/- Spic+/spleens. In contrast, Spib-/- and Spib-/- Spic+/- spleens contained elevated frequencies and
absolute numbers of T1 B cells compared to WT spleens, although there was no
quantitative difference in the T1 population between Spib-/- and Spib-/- Spic+/- mice. For
T2 populations, Spib-/- spleens contained fewer cells than WT, and both frequency and
absolute numbers of T2 cells were increased in Spib-/- Spic+/- spleens (Fig. 3.5D). To
confirm that T2 B cell numbers were increased in Spib-/- Spic+/- spleens compared to Spib/-

, splenic B cells were examined using an alternative staining scheme based on CD21 and

IgM expression (Fig. 3.6A). Absolute numbers of T2 B cells were significantly reduced
in Spib-/- spleens compared to WT, and were rescued in Spib-/- Spic+/- spleens using the
alternative staining scheme (Fig. 3.6B). In summary, these results showed that reduced
Spi-C in Spib-/-Spic+/- mice resulted in a substantial rescue of the frequency of T2 cells in
the spleen of Spib-/- mice.

3.2.4 LPS and anti-IgM mediated proliferation is rescued in Spib-/-Spic+/- B
cells compared to Spib-/- B cells
B cells lacking Spi-B have been previously reported to have impaired
proliferative responses to either LPS or anti-IgM (Garrett-Sinha et al, 1999; Su et al,
1997). To determine whether Spic heterozygosity could rescue functional defects of Spib
knockout B cells, proliferation of Spib-/- and Spib-/-Spic+/- splenic B cells in response to
LPS or anti-IgM was assessed using a MTT proliferation assay. Compared to WT B cells,
Spib-/- B cells proliferated poorly in response to LPS or anti-IgM (Fig. 3.7A). In contrast,
Spib-/-Spic+/- B cells were substantially rescued for LPS or anti-IgM-mediated
proliferation compared to Spib-/- B cells (Fig. 3.7A-B). To confirm the proliferation
rescue, LPS-mediated proliferation was measured by flow cytometry following staining
B cells with carboxyfluorescein succinimidyl ester (CFSE) (Fig. 3.7C). Fewer cells
underwent cell division in Spib-/- B cells stimulated with LPS compared to WT B cells.
However, more proliferating cells were detected in Spib-/-Spic+/- B cells compared to
Spib-/- B cells (Fig. 3.7D). Therefore, these results suggested that B cell proliferation in
response to LPS or anti-IgM is positively regulated by Spi-B, but negatively regulated by
Spi-C.
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Figure 3.5. Spib-/-Spic+/- mice have elevated transitional B cells and restored transitional2 B cells compared to Spib-/- mice.
(A) Total transitional B cell populations were quantified in WT, Spib-/-, and Spib-/-Spic+/mice. Splenocytes were stained with CD93 and B220 and analyzed by flow cytometry.
The dashed-box represents total transitional B cells. (B) Increased frequencies and
absolute number of total transitional B cells in spleens of Spib-/- and Spib-/-Spic+/- mice. (C)
Transitional B cell subsets T1 (Top left box, IgM hiCD23-), T2 (Top right box,
IgMhiCD23+), and T3 (Bottom right box, IgMlowCD23+) were quantified in WT, Spib-/-, and
Spib-/-Spic+/- mice. Cells were gated on B220 and CD93 and analyzed for IgM and CD23
staining by flow cytometry. (D) Increased T2 subset in Spib-/-Spic+/- compared to Spib-/mice. Quantitation of results shown in (C). Data is shown as mean frequency and
absolute numbers of gated B220+CD93+ splenocytes. For B and D, data is shown as the
mean and SD of 9 individual mice. *p<0.05; **p<0.01; ***p<0.001.

103

104

Figure 3.6. Spib-/-Spic+/- mice have restored transitional-2 B cells compared to Spib-/mice.
(A) T2 B cells (IgM+CD21int; dashed box) were quantified in WT, Spib-/-, and Spib-/Spic+/- mice. Cells were gated on B220 and CD93 and analyzed for IgM and CD21
staining by flow cytometry. (B) Restored T2 subset in Spib-/-Spic+/- compared to Spib-/mice. Quantitation of results shown in (A). Data is shown as mean and SD for frequency
and absolute numbers of gated B220+CD93+ splenocytes from 7 individual mice.
*p<0.05.
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To determine if the Spib-/-Spic+/- B cell phenotype could be reversed by ectopic
expression of Spi-C, Spib-/-Spic+/- mice were crossed to Eμ-Spi-C transgenic mice (Zhu et
al, 2008). Spleens from Eμ-Spi-C Spib-/-Spic+/- mice contained fewer cells than Spib-/Spic+/- spleens (Fig. 3.7E). Flow cytometry analysis was performed on Eμ-Spi-C Spib-/Spic+/- spleens to assess for differences in B cell populations. Frequencies of MZ and FO
B cells in Eμ-Spi-C Spib-/-Spic+/- spleens were unchanged compared to Spib-/-Spic+/spleens, however, there was a significant reduction in the absolute number of MZ and FO
B cells in Eμ-Spi-C Spib-/-Spic+/- mice (Fig. 3.7F). Proliferation of Eμ-Spi-C Spib-/-Spic+/B cells following LPS stimulation was assessed by CFSE staining. Compared to Spib-/Spic+/- B cells, frequencies of proliferating Eμ-Spi-C Spib-/-Spic+/- B cells decreased (Fig.
3.7G). This data suggests that reintroducing Spi-C using a lymphocyte-specific transgene
reverses the Spib-/-Spic+/- B cell proliferation phenotype.
Since anti-IgM mediated proliferation was restored in Spib-/-Spic+/- B cells
compared to Spib-/-, it was possible that Spib-/-Spic+/- B cells could have restored BCR
signaling. To test for this, phosphorylated levels of Syk were measured in B cells using
flow cytometry (Fig. 3.7H). There was a detectable increase in phospho-Syk levels
following anti-IgM stimulation; however, there was no difference in the increase between
WT, Spib-/-, and Spib-/-Spic+/- B cells (Fig. 3.7I). Next, total Syk was measured in B cells
using immunoblot analysis. There was a noticeable increase in total Syk protein in Spib-/-,
and Spib-/-Spic+/- B cells compared to WT B cells (Fig. 3.7J). Therefore, the restoration in
BCR signaling in Spib-/-Spic+/- B cells is likely independent of Syk.
It was previously reported that Spib-/- mice had normal basal levels of all Ig
isotypes (Su et al, 1997). To determine whether reduced Spi-C had an effect on isotype
switching in Spib-/-Spic+/- mice, basal serum levels of different immunoglobulin were
measured by ELISA. No significant differences in basal levels of IgM (Fig. 3.8A) or
IgG2b (Fig. 3.8B) were measured between WT, Spib-/-, and Spib-/-Spic+/- mice. Therefore,
the data suggests that Spi-C does not alter basal levels of Ig isotypes in Spib-/-Spic+/mice.
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Figure 3.7. B cell proliferation is rescued in Spib-/-Spic+/- mice compared to Spib-/- mice.
(A) Spib-/-Spic+/- B cells have significantly increased proliferation compared to Spib-/- B
cells. Proliferation was measured using an MTT proliferation assay. Data shown is the
mean and SD of triplicate wells and is a representative of 5 experiments. (B) Quantitation
of 5 experiments from (A) showing proliferation index, which is calculated by
normalizing corrected OD
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values to the untreated WT control. Data is shown as mean

and SEM. (C) Proliferation assessed by flow cytometry following CFSE staining on WT,
Spib-/-, and Spib-/-Spic+/- B cells. Gate shown represents the frequency of proliferating
cells. Data shown is a representative of 4 individual experiments (D) Quantitation of
CFSE experiments as performed in (C) showing frequency of cells that underwent cell
division. (E) Cell counts based on total cells isolated from the spleens of Spib-/-Spic+/- and
Eµ-Spi-C Spib-/-Spic+/- mice. (F) Quantitation of the frequency and absolute number of
MZ and FO mature B cells (B220+CD93-) in the spleens of Spib-/-Spic+/- and Eµ-Spi-C
Spib-/-Spic+/- mice. FO and MZ B cell populations were quantified based on CD23 and
IgM surface expression measured by flow cytometry. For E and F, data is shown as mean
and SD of 5 individual mice. (G) Proliferation assessed by flow cytometry following
CFSE staining on Spib-/-Spic+/- and Eµ-Spi-C Spib-/-Spic+/- B cells. Data is shown as mean
and SD for 4 individual experiments. (H) Phospho-Syk levels were assessed in WT,
Spib-/-, and Spib-/-Spic+/- B cells using flow cytometry. Splenocytes were stained with
B220, stimulated with anti-IgM for 2 minutes or untreated, and then stained with
phospho-Syk prior to analysis. (I) Quantitation of phospho-Syk levels in B220+
splenocytes following anti-IgM stimulation. Phospho-Syk levels are shown as normalized
phospho-Syk MFI of anti-IgM to untreated. Data is shown as the mean and SD of 5
individual experiments. (J) Syk protein expression measured in WT, Spib-/-, and Spib-/Spic+/- B cell lysates. Immunoblot was performed using anti-Syk antibody and anti-βActin as a loading control. Data shown is a representative of 3 individual experiments.
For A-D and G, total B cells were enriched by magnetic separation and stimulated with
LPS or anti-IgM for 72 hours. *p<0.05; **p<0.01; ***p<0.001.
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Figure 3.8. Equivalent basal serum antibody levels between WT, Spib-/-, and Spib-/-Spic+/mice.
(A) IgM and (B) IgG2b serum levels measured by ELISA. Data shows mean and
standard deviation (n=6).
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3.2.5 Spi-C represses Nfkb1 promoter activation by Spi-B
Finally, a potential mechanism for Spi-C’s regulation of B cell proliferation was
investigated. Stimulation of B cells with LPS or anti-IgM results in NF-κB transcription
factor activation (Pone et al, 2010). P50 (encoded by Nfkb1) is required for murine B cell
proliferation in response to LPS or anti-IgM (Sha et al, 1995). We recently showed that
PU.1 and Spi-B are required for Nfkb1 transcription in B cells, and retroviral transduction
with p50 substantially rescues LPS-induced proliferation of Spi1+/-Spib-/- B cells (Li et al,
2015). Therefore, it was determined whether restored proliferation in Spib-/-Spic+/- B cells
was associated with increased mRNA transcript levels of Nfkb1 compared to Spib-/- B
cells. RT-qPCR was performed on cDNA synthesized from MZ and FO B cells sorted
from Spib-/- and Spib-/-Spic+/- spleens. Steady-state Nfkb1 mRNA transcript levels were
increased in MZ and FO B cells of Spib-/-Spic+/- mice compared to Spib-/- mice (Fig.
3.9A), suggesting that Spi-C may negatively regulate Nfkb1 in B cells.
To assess whether Spi-B and Spi-C regulate Nfkb1 directly, the murine Nfkb1
promoter sequence was aligned with multiple species using a published transcription start
site (TSS) for reference (Cogswell et al, 1993). The Nfkb1 5’ UTR contained two highly
conserved ETS binding sites predicted among all species near the TSS using
MatInspector software (Fig. 3.9B). Next, the mouse Nfkb1 proximal promoter was cloned
as described in Materials & Methods and ligated into the pGL3-basic luciferase reporter
vector. Site directed mutagenesis was performed to mutate two predicted ETS binding
sites closest to the transcriptional start site by substituting GGAA (TTCC on complement
strand) with GGAC (GTCC), which has been previously reported to abolish Spi-B
binding (DeKoter et al, 2010; Xu et al, 2012) (Fig. 3.9C). To determine whether Spi-B
and Spi-C regulate Nfkb1 transcription in opposing fashion, luciferase assays were
performed using transient transfection of WEHI-279 B lymphoma cells that ectopically
express 3XFLAG tagged Spi-B or Spi-C (DeKoter et al, 2010; Xu et al, 2012). WEHI279 cells infected with an empty MIGR1 virus were used as a control (WEHI-279
MIGR1). Expression of 3XFLAG Spi-B and Spi-C protein was confirmed by anti-FLAG
immunoblot analysis in infected cell lines (Fig. 3.9D). The Nfkb1 promoter was active in
WEHI-279 MIGR1 cells, and mutation of the ETS sites impaired its activation (Fig.
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3.9E). WEHI-279 Spi-B cells displayed a higher level of activation compared to WEHI279 MIGR1 cells, whereas mutation of the ETS sites reduced Nfkb1 activation.
Interestingly, the activity of the Nfkb1 promoter in WEHI-279 Spi-C cells was lower than
both WEHI-279 MIGR1 and WEHI-279 Spi-B cells, and mutation of the ETS site
resulted in no change of activity (Fig. 3.9E). To confirm that Spi-C expression decreased
Nfkb1 transcriptional activation, luciferase activity was measured following cotransfection of a Spi-C expression vector (pcDNA3 Spi-C) and the pGL3-Nfkb1 vector
into WEHI-279 Spi-B cells. Co-transfection with pcDNA3 Spi-C resulted in decreased
Nfkb1 activation compared to co-transfection with the vector control (pcDNA3) (Fig.
3.9F). These results suggest that Spi-B transcriptionally activates Nfkb1, and Spi-C
inhibits Nfkb1 transcription.
We recently showed that PU.1 and Spi-B directly interact with the Nfkb1
promoter to activate its transcription (Li et al, 2015). To determine if Spi-C directly
interacts with the Nfkb1 promoter, ChIP analysis was performed using anti-Spi-C and
anti-FLAG Ab on chromatin isolated from WEHI-279 Spi-C and WEHI-279 MIGR1
cells. Relative amounts of immunoprecipitated DNA were determined by qPCR from the
Nfkb1 promoter region, and the Gapdh promoter as a negative control. ChIP analysis
confirmed that Spi-C was significantly enriched at the Nfkb1 promoter compared to the
Gapdh promoter in WEHI-279 Spi-C cells, but not WEHI-279 MIGR1 cells (Fig. 3.9G).
Together, these data indicate that Spi-C directly interacts with the Nfkb1 promoter,
suggesting that it opposes Spi-B-mediated activation of Nfkb1 transcription in B cells.
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Figure 3.9. Spi-C inhibits activation of the Nfkb1 promoter by Spi-B.
(A) Measurement of transcript levels of Nfkb1 in Spib-/-Spic+/- compared to Spib-/- B cells.
RT-qPCR analysis was performed on RNA prepared from unstimulated sorted FO and
MZ B cells. mRNA transcript levels of genes indicated on the X-axis were quantified
after normalizing to β2 microglobulin (B2m). Data is shown as mean and SD, and is a
representative of 3 individual mice. (B) Alignment of the annotated Nfkb1 promoter
between multiple species, showing nucleotides 105-130 of the conserved 213 bp region.
Grey text represents conserved nucleotides, and boxes indicate predicted PU.1/Spi-B
binding sites with similarity score and strand location (+/-) listed. Circled nucleotide
represents known TSS in the human Nfkb1 promoter. Dots represent TSS upstream or
downstream of the annotated sequence. (C) Schematic of luciferase reporter vector. The
Nfkb1 promoter was cloned by PCR and ligated into pGL3-basic. ETS binding sites (wt)
were mutated (mut) using site-directed mutagenesis. (D) WEHI-279 B cell lymphoma
cell lines were generated that overexpress 3XFLAG-Spi-B or Spi-C. Immunoblot
analysis demonstrates the overexpression levels of Spi-B or Spi-C in these cell lines. (E)
Overexpression of Spi-C inhibits activation of the Nfkb1 promoter. Mutation of the
predicted ETS binding sites reduces promoter activity in WEHI-279 MIGR1 and WEHI279 Spi-B cells. (F) Spi-C expression in WEHI-279 Spi-B cells decreases Nfkb1
activation. WEHI-279 Spi-B cells were co-transfected with a Spi-C expression vector
(pcDNA3 Spi-C) along with the luciferase vectors. In E and F, cells were transfected with
the plasmids indicated on the x-axis. The y-axis indicates fold-induction of luciferase
activity relative to pGL3-basic. Luciferase activity was normalized by transfection with
Renilla luciferase expression vector. Data shown is the mean and SEM of three
independent experiments. (G) Spi-C directly binds to the Nfkb1 promoter. ChIP analysis
was performed on WEHI-279 MIGR1 and WEHI-279 Spi-C cells immunoprecipitated
with anti-FLAG or anti-Spi-C Ab. Data shows percent enrichment relative to input for
Spi-C interaction with Nfkb1 and Gapdh promoters. Statistics was performed using a
paired Student’s t-test. Error bars represent SEM from 6 independent experiments.
**p<0.01; *p<0.05.
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3.3 Discussion
The purpose of these experiments was to understand how Spi-C contributes to B
cell development and function. Spi-C heterozygosity restored many aspects of the Spib-/phenotype. Spib-/-Spic+/- mice had restored numbers of FO and T2 B cells in their spleens
relative to Spib-/- mice. Furthermore, proliferation in response to LPS and anti-IgMmediated stimulation was restored in Spib-/-Spic+/- B cells compared to Spib-/- B cells.
Investigation of a potential mechanism for the Spib-/-Spic+/- phenotypic rescue revealed
that steady-state levels of Nfkb1 were elevated in sorted FO and MZ B cells from Spib-/Spic+/- spleens compared to Spib-/- spleens. Ectopic expression of Spi-B in B cells resulted
in increased Nfkb1 promoter activity, which was dependent on the ETS binding site.
Conversely, overexpression of Spi-C inhibited Nfkb1 activation by Spi-B. ChIP and
ChIP-seq analysis demonstrated that both Spi-B and Spi-C are capable of directly binding
to the Nfkb1 promoter. In summary, these results suggest that Spi-C opposes Spi-B in B
cell transcriptional regulation.
Intercrosses of Spib-/-Spic+/- mice generated Spib-/-Spic-/- mice at a frequency less
than 1% of live births. Similar findings were reported where intercrosses of Spic+/- mice
generated only 9% Spic-/- (Kohyama et al, 2009). Previous studies have demonstrated that
embryos injected with Spic-siRNA resulted in reduced rate of blastocyst development
(Kageyama et al, 2006). It is possible that Spi-B and Spi-C may have overlapping roles in
prenatal development, and therefore embryonic death may be occurring at the blastocyst
stage in Spib-/-Spic-/- mice. Therefore, low birth frequency of Spib-/-Spic-/- mice is likely
due to reduced embryonic or fetal viability.
Few target genes for Spi-C have been identified in B cells, and Spi-C was
reported to function either as an activator or as a repressor of gene transcription. It is
possible that altered expression of other unidentified target genes may contribute to the
Spib-/-Spic+/- B cell phenotype. Spi-C ectopically expressed in pro-B cells can directly
bind and oppose transcription of the Fcgr2b gene mediated by PU.1 (Schweitzer et al,
2006). In contrast, transcription of the gene Fcer2a, encoding CD23, was reported to be
directly activated by Spi-C in WEHI-279 Spi-C cells (DeKoter et al, 2010). Earlier
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reports showed that Spi-C cooperated with STAT6 to directly induce transcription of IgE
under the control of IL-4 (Carlsson et al, 2006). In macrophages, Spi-C was reported to
directly activate Vcam1 transcription (Kohyama et al, 2009). Our data demonstrated that
Spi-C directly opposes transcriptional activation of Nfkb1 by preventing Spi-B and
possibly PU.1 from binding to the Nfkb1 promoter in B cells. In summary, Spi-C is
capable of both activation and repression of its target genes, and can also transcriptionally
regulate target genes by preventing other transcription factors from binding.
Previous studies have demonstrated that the transcription factors PU.1 and Spi-B
are required to maintain proper levels of Nfkb1 in B cells (Li et al, 2015). Spi-B directly
binds to the Nfkb1 promoter and activates transcription. In contrast, Spi-C directly binds
to the Nfkb1 promoter, but does not activate transcription. Therefore, decreased Spi-C
expression may reduce its occupancy of the Nkfb1 promoter in Spib-/-Spic+/- B cells,
permitting increased activation of Nfkb1 by PU.1. Elevated Nfkb1 transcript levels in
Spib-/-Spic+/- B cells compared to Spib-/- B cells suggest that Spi-C and Spi-B oppose each
other to regulate appropriate Nfkb1 levels. Spib-/- and Nfkb1-/- B cells proliferate similarly
to LPS and anti-IgM. LPS stimulated Nfkb1-/- B cells fail to proliferate, and anti-IgM
stimulation results in reduced proliferation (Sha et al, 1995). Overall, elevated Nfkb1
expression in Spib-/-Spic+/- B cells compared to Spib-/- B cells may sufficiently explain the
rescue in proliferation.
Spib-/-Spic+/- mice have restored FO and T2 B cell numbers compared to Spib-/mice, indicating that Spi-B and Spi-C regulate peripheral B cell differentiation. FO and
T2 cell differentiation both require NF-κB signaling and BCR signaling. Transitioning
from a T1 to T2 B cell requires non-canonical NF-κB signals and basal BCR signals, and
maturation of a T2 to a FO B cell requires canonical NF-κB signals and strong BCR
signaling (Pillai & Cariappa, 2009). Nfkb1-/-Nfkb2-/- mice have a developmental block at
the T2 stage and fail to generate any mature B cells (Claudio et al, 2002). Therefore,
elevated Nfkb1 expression in developing Spib-/-Spic+/- could be sufficient to explain the
restored FO B cell population. It is also conceivable that Spi-C may also be a negative
regulator of c-Rel expression, as PU.1 and Spi-B have been previously reported to
directly activate Rel transcription (Hu et al, 2001). Alternatively, it is possible that FO
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and T2 B cells in Spib-/-Spic+/- have a longer life-span than Spib-/- B cells, which could
contribute to its restoration.

Spib-/- B cells have impaired BCR signaling and thus

proliferate poorly in response to anti-IgM stimulation (Garrett-Sinha et al, 1999; Su et al,
1997). Transgenic Spi-C expression in B cells results in reduced transcript levels of the
BCR signaling genes Btk and Blnk in FO B cells (Zhu et al, 2008). Restored proliferative
response to anti-IgM in Spib-/-Spic+/- B cells compared to Spib-/- B cells suggests that BCR
signaling is possibly restored due to reduced Spi-C expression. Since WT, Spib-/-, and
Spib-/-Spic+/- B cells are capable of phosphorylating Syk at equivalent levels following
anti-IgM stimulation, the rescue in BCR signaling is likely downstream of Syk.
Therefore, rescued FO and T2 B cells in Spib-/-Spic+/- spleens might be caused by a
combination of restored NF-κB and BCR signalling.
It is possible that aspects of the B cell phenotype of Spib-/-Spic+/- mice are not
cell-intrinsic. However, evidence was provided for a cell-intrinsic effect of Spi-C on B
cell proliferation using the Eµ-Spi-C transgenic mouse. In this mouse model the Spi-C
transgene is under the control of a lymphocyte-specific Eµ intronic enhancer. We found
that crossing this transgenic mouse to Spib-/-Spic+/- mice (Eμ-Spi-C Spib-/-Spic+/-) resulted
in a reduction in proliferation from isolated B cells, suggesting Spi-C has a cell-intrinsic
effect on B cell function. Furthermore, overexpression of Spi-C in Eμ-Spi-C Spib-/-Spic+/mice reduced the number of FO and MZ B cells, suggesting a cell-intrinsic role for Spi-C
in B cell development.
In summary, our results demonstrate a novel mechanism for Spi-C as a negative
regulator of B cell development and function. Understanding transcriptional regulation in
B cells has human health implications, since dysfunctional B cell development can lead
to leukemia of the B cell lineage (Sokalski et al, 2011; Xu et al, 2012). Furthermore,
antibody formation in B cells is transcriptionally regulated, so understanding potential
activators and repressors of this process can improve interventions for vaccine
development. Further analysis on mice lacking Spi-B and reduced Spi-C can provide
additional insight into other genes involved in B cell development, function, and disease.
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3.4 Materials and Methods
3.4.1 Generation and breeding of mice
Mice were housed at Western University’s Health Sciences animal facility (London,
Ontario, Canada) and monitored under an approved animal use subcommittee protocol in
accord with Western University Council on Animal Care. C57BL/6 (WT) mice were
purchased from Charles River Laboratories (Pointe-Claire, Quebec, Canada). Spib+/Spic+/- mice were backcrossed to C57BL/6 mice for 5 generations prior to the generation
of Spib-/-Spic+/- mice. Spib-/-Spic+/- mice were generated by mating male and female Spib-/Spic+/- mice. E-Spi-C Spib-/-Spic+/- mice were generated by mating E-Spi-C+ male
mice to Spib-/-Spic+/- females. Genotyping was performed by PCR as previously
described (DeKoter et al, 2010; Kohyama et al, 2009). All experiments were performed
on mice aged 6-12 wks.

3.4.2 B cell enrichment and proliferation analysis
RBCs were removed from spleen cell suspensions by hypotonic lysis with ammonium
chloride solution. B cells were enriched by negative selection using biotin-conjugated
anti-CD43 (S7) Ab, streptavidin (SA) microbeads, LD depletion columns, and a
QuadroMACS™ separation unit (Miltenyi Biotec, Germany). B cells (2x105/well) were
plated in 96-well flat bottom plates and stimulated with LPS (10 μg/mL, List Biological
Laboratories), anti-IgM Ab (50 μg/mL, affinity pure F(ab’)2 fragment, or goat antimouse IgM, μ chain specific; Jackson ImmunoResearch Laboratories), in complete
IMDM. Proliferation was assessed after 72 h incubation at 37°C with a TACS® MTT Cell
Proliferation assay (Trevigen, Gaithersburg, MD) used according to the manufacturer’s
instructions. For CFSE analysis, 10x106 B cells were stained with 5 μM of CFSE
(Biolegend, San Diego, CA) for 5 min at room temperature prior to plating. Frequency of
stained cells was assessed after 72 h incubation at 37°C by flow cytometry.
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3.4.3 Flow cytometry
Antibodies and reagents purchased from eBioscience (San Diego, CA), BD Bioscience
(Franklin Lakes, NJ), or BioLegend included 7-AAD, CFSE, brilliant violet 421
conjugated anti-CD45R/B220 (Ra3-6B2), allophycocyanin (APC)-conjugated IgM
(II/41), APC-conjugated Annexin V, biotin-conjugated anti-CD43 (S7), phycoerythrin
(PE) conjugated CD93 (AA4.1), PE conjugated anti-BP-1 (BP-1), PE-conjugated antiCD19 (1D3), PE-conjugated phospho-Syk (moch1ct), fluorescein isothiocynate (FITC)conjugated CD24 (30-F1), FITC-conjugated anti-CD21/CD35 (eBio8D9), FITCconjugated anti-CD23 (B3B4), and PE-Cy5-conjugated streptavidin. Cells were blocked
with purified anti-CD16/CD32 (Mouse BD Fc BlockTM). Intracellular staining was
performed using a two-step protocol and intracellular fixation and permeabilization
buffer set obtained from eBioscience. Antibody-stained cell analysis was performed
using FACSCalibur and LSRII systems, and sorting was performed using a FACSAriaIII
system (BD Biosciences). Sorted cells were determined to be >98% purity. Data analysis
was performed using FlowJo software (TreeStar Inc., Ashland, OR).

3.4.4 Reverse transcription-quantitative PCR
RNA was isolated with Trizol reagent (Invitrogen, Burlington, Ontario, Canada). cDNA
was synthesized using an iScript cDNA Synthesis Kit (Bio-Rad, Mississauga, Ontario,
Canada), and qPCR was performed with a Rotor-Gene 6000 instrument (Corbett Life
Sciences, Valencia, CA). Relative mRNA transcript levels were normalized to β2m and
compared between samples using the comparative threshold cycle method. Calculations
were performed using REST© 2009 software (Pfaffl et al, 2002). Primer sequences are
listed in Table 3.2.

3.4.5 Immunoblot analysis
Lysates were prepared using Laemelli buffer and applied to 8%-10% SDS
polyacrylamide gels for electrophoresis. Proteins were transferred to nitrocellulose
membranes using a Trans-Blot Semi-Dry system (Bio-Rad), and membranes were
blocked for 1 hour in 5% milk in TBST. Membranes were probed with anti-Spi-C (Aviva
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Systems Biology, San Diego, CA), anti-Flag (M2, Sigma Aldrich, St. Louis, MO), antiSyk (C-20, Santa Cruz Biotechnology, Dallas, Texas), or anti-β-Actin (I-19, Santa Cruz
Biotechnology) Ab, and diluted to manufacturer recommended concentrations in 1%
milk/TBST overnight at 4°C. A secondary horseradish peroxidase-conjugated anti-goat
Ab was incubated in 1% milk/TBST. Membranes were washed and visualized with
SuperSignal West Pico reagent (Thermo-Fisher Scientific).

3.4.6 ELISAs
Serum was collected and quantified for IgG2b and IgM. ELISA kits were purchased
from eBioscience and performed according to the manufacturer’s instructions. ELISA
plates were analyzed using an Epoch microplate spectrophotometer with Gen5 software
(BioTek, Winooski, VT).

3.4.7 Plasmids and cloning
Spi-C cDNA was cloned into the hemagglutinin (HA) tag-containing pcDNA3 vector as
previously described (Schweitzer et al, 2006). The Nfkb1 promoter was amplified from
C57BL/6 genomic DNA by PCR using LA-TAQ (TaKaRa; Clontech Laboratories Inc,
Mountain View, CA), purified, and cloned into the pSC-A vector using a PCR cloning kit
(Agilent Technologies, La Jolla, CA). A 468bp Nfkb1 promoter was PCR amplified using
a forward primer containing a HindIII site and subcloned. The promoter was HindIII
digested from pSC-A and ligated into the HindIII site of the pGL3-basic
(Promega, Madison, WI) luciferase reporter vector. ETS binding sites were mutated using
the QuickChange lightning site-directed mutagenesis kit according to the manufacturer’s
instructions (Agilent Technologies). Constructs were verified by DNA sequencing.
Transfection-quality plasmid DNA was prepared by growth in DH5α bacteria and
purified with plasmid maxi prep kit (Geneaid, New Taipei City, Taiwan). All restriction
enzymes were purchased from New England Biolabs (Ipswich, MA). Primer sequences
used for cloning are listed in Table 3.2.
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Table 3.2. Forward and reverse primers used for RT-qPCR analysis, cloning, and site
directed mutagenesis.
Primer Name

DNA Sequence (5’ -> 3’)

B2m fwd 5’-TGG CTC ACA CTG AAT TCA CCC CCA-3’
rev 5’-TCT CGA TCC CAG TAG ACG GTC TTG-3’
Gapdh promoter ChIP fwd 5’-GTCTGTTATATGGGCGTCCTGTCA-3’
rev 5’-CGTTCACACCGACCTTCACCATTT-3’
Nfkb1 fwd 5’-GCT GAG TCC TGC TCC TTC TAA A-3’
rev 5’-CCT CTG TGT AGC CCA TCT GTT GC-3’
Nfkb1 promoter ChIP fwd 5’-TCC GTC TGT CTG CTC TCT-3’
rev 5’-GAA AGC AGT GAG GTA AGC CCA AC-3’
Nfkb1 Promoter fwd 5’-CCC AAA GAA TAA AGA CGC TCA AAT GC-3’
rev 5’-TCA GAA GAC CGA AGG AAG CCT ACA-3’
Nfkb1 Sublone w/ HindIII fwd 5’-CAA GCT TAC CTC CCG CCC CC-3’
Rev 5’-CCT GGA GAT GCG GCG CGG-3’
pGL3-Nfkb1 Mutation 5’-TCT CGA CGT CAG TGG GAA TGT CCA GC-3’
pGL3-Nfkb1 Mutation anti 5’-TCG CTC ACT CTC TCA CGT CCT GGC TGG-3’
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3.4.8 Transient transfection
WEHI-279 MIGR1, MIG-3XFLAG-Spi-B, and MIG-3XFLAG-Spi-C cells were
generated as previously described (DeKoter et al, 2010; Xu et al, 2012). Cells in mid to
early log phase growth were washed three times with serum-free DMEM (4.5g/L, Wisent
Inc, St-Bruno, Quebec) and incubated for 10 minutes at room temperature with 10 μg of
each luciferase reporter plasmid and 1 μg of pRL-TK (Promega). Cell-DNA mixtures
were electroporated at 220 V and 950 mF using 4-mm gap cuvettes with a GenePulser II
with Capacitance Extender (Bio-Rad), incubated at room temperature for 10 min, then
transferred to 6-well culture plates in complete DMEM and incubated at 37°C for 24
hours. A Dual-Luciferase Reporter Assay System (Promega) was performed on cell
lysates. Light production was measured using a Lumat LB 9507 tube luminometer
(Berthold Technologies, Oak Ridge, TN).

3.4.9 ChIP experiments
Chromatin was prepared from enriched B cells as previously described (Sokalski et al,
2011; Xu et al, 2012). In brief, cells were cross-linked and lysed followed by sonication.
Sonicated chromatin was incubated overnight at 4°C with anti-Spi-C (generated by
Fulkerson lab) and anti-FLAG (M2, Sigma-Aldrich) conjugated to protein G DynaBeads
(Invitrogen). Magnetic bead complexes were enriched using a MagneSphere®
Technology Magnetic Separation Stand (Promega) and washed. Immunocomplexes were
eluted and cross-linked chromatin was reversed overnight at 65°C. DNA was purified
using a QIAquick PCR purification kit (Qiagen, Limburg, Netherlands). Enrichment was
measured using qPCR of immunoprecipitated DNA using primers indicated in Table EI.

3.4.10 ChIP-Seq Analysis
ChIP-seq experiments were performed using mouse WEHI-279 cells. Cells were spininfected with a MIGR1 vector for expression of 3XFLAG-PU.1 or 3XFLAG-Spi-B.
Immunoprecipitation was performed using anti-FLAG microbeads (M2, Sigma-Aldrich).
Purified chromatin was sequenced on an Ilimuna HiSeq at the BC cancer research
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agency. Peak finding and data analysis was performed using Galaxy Suite (Blankenberg
et al, 2010; Giardine et al, 2005; Goecks et al, 2010). Reads were aligned to the reference
genome (NCBI37/mm9), using BOWTIE (Langmead et al, 2009). Peaks were called
using MACS version 1.0.1 (Zhang et al, 2008) with default parameters, a P-value cutoff
for peak detection of 1e-05 and an effective genome size of 2.7e+9 bp. The ChIP-seq data
from this publication have been submitted to the Gene Expression Omnibus database
(http://www.ncbi.nlm.nih.gov/geo) and assigned the identifier GSE48891 and GSE58128.

3.4.11 Statistical analysis
Statistical significance was determined using one-way or two-way ANOVA analysis with
a Bonferroni post-test unless otherwise indicated. P values ≤0.05 were considered
significant. For all figures, *P ≤0.05, **P ≤0.01, and ***≤P 0.001. Statistical analysis
was performed using Prism 5.0 (Graph-Pad Software).
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Chapter 4

4

Overall discussion and future directions
This thesis describes the ability of the transcription factors PU.1, Spi-B, and Spi-

C to control B cell development and proliferative function. The hypothesis that PU.1 and
Spi-B were required for positively regulating components of TLR responses was tested.
In chapter 2, B cells from PUB (Spi1+/-Spib-/-) mice were shown to be impaired for TLRmediated proliferation responses. The impairment in PUB B cells was attributed to
reduced levels of p50 protein, which is encoded by the Nfkb1 gene. It was demonstrated
that both PU.1 and Spi-B are capable of directly binding to the Nfkb1 promoter, and the
ETS binding sites within the promoter were required for efficient transcription of the
gene. Impaired TLR-mediated proliferation was restored upon retroviral reinsertion of
p50 into PUB B cells. These results suggest that Nfkb1 activation by PU.1 and Spi-B is
important for TLR-initiated B cell responses.
Chapter 3 characterized the role of Spi-C in B cells. The hypothesis that Spi-C
inhibited target genes of PU.1 and Spi-B was tested. By generating the novel mouse
model Spib-/-Spic+/- and comparing it to Spib-/- mice, it was determined that Spi-C has a
functionally distinct role compared to Spi-B. Spi-C heterozygosity restored many aspects
of the Spib-/- phenotype, including a restoration in FO and T2 B cell numbers in the
spleen, and restored LPS and anti-IgM-mediated B cell proliferation. Nfkb1 was
hypothesized to participate in the mechanism for the Spib-/-Spic+/- phenotype. Transcript
levels of Nfkb1 were elevated in Spib-/-Spic+/- B cells compared to Spib-/- B cells. In B cell
lines overexpressing Spi-B, Nfkb1 promoter activity was substantially elevated; however,
Nfkb1 promoter activity was significantly reduced in B cell lines overexpressing Spi-C. It
was demonstrated that Spi-C directly bound to the same sites as PU.1 and Spi-B at the
Nfkb1 promoter. Therefore, Spi-C directly opposes Spi-B transcriptional regulation in B
cells.
These studies have identified a mechanism by which PU.1, Spi-B, and Spi-C
regulate development and proliferative function in B cells. PU.1 and Spi-B are capable of
each individually binding directly to the Nfkb1 promoter to activate its expression (Figure
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4.1A). In contrast, Spi-C directly binds to the same Nfkb1 promoter region and represses
Nfkb1 activation (Figure 4.1B). Since all three transcription factors can bind to the same
regions, we hypothesize that Spi-C can function to compete with PU.1 and Spi-B for
binding at the same sites within the Nfkb1 promoter. However, the mechanism of
activation/repression through direct competition for binding can be complex.
There are many aspects of transcriptional regulation which can be addressed in
the future. Repression of Nfkb1 by Spi-C could be mediated through recruitment of other
transcription factors or histone modifying proteins which affect the accessibility of the
Nfkb1 promoter. Likewise, the activation of Nfkb1 by PU.1 and Spi-B can involve
interactions with distal enhancer sites to recruit additional transcription factors to activate
gene promoters or modulate chromatin accessibility. A high-throughput method of ChIPmass spectrometry could identify the plethora of interacting proteins recruited by PU.1,
Spi-B, or Spi-C (Wang et al, 2013). Furthermore, using chromosome conformation
capture (3C) assays would elucidate the interactions between distal regulatory enhancers
or insulators (Hagege et al, 2007). Overall, determining what transcription factors or
associated proteins are recruited by PU.1, Spi-B, and Spi-C could improve our
understanding of transcriptional regulatory networks.
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Figure 4.1. A model of transcriptional regulation of Nfkb1 by PU.1, Spi-B, and Spi-C.
(A) PU.1 and Spi-B directly bind to the Nkfb1 promoter to activate transcription. (B) SpiC can directly bind to the same Nkfb1 promoter region to inhibit its transcription.
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4.1 Transcriptional Nfkb1 regulation
This thesis described transcriptional regulation of Nfkb1 by PU.1, Spi-B, and SpiC in B cells. Using the PUB mouse model, it was demonstrated that PU.1 and Spi-B
directly regulated Nfkb1 transcription. Spi-C was shown to be directly responsible for
repressing Nfkb1 transcription by interacting with the same sites in the promoter. There
are multiple ETS binding sites within the Nfkb1 promoter, and it has now been
demonstrated that at least the first two sites are required for Nfkb1 activation. While both
ChIP and ChIP-seq analysis have validated direct PU.1, Spi-B, and Spi-C binding to the
Nfkb1 promoter, there are still many unknown aspects of its regulation. Other ETS family
transcription factors are likely involved with Nfkb1 activation in B cells. The ETS
transcription factor Ets-1 was previously reported to be required for activating Nfkb1 in
human Jurkat T cells at a ETS binding site further downstream of the TSS (Lambert et al,
1997). Since Ets-1 is also expressed in B cells and is required for the generation of
mature B cells (Eyquem et al, 2004; Garrett-Sinha, 2013), it is likely also involved with
regulating Nfkb1 expression. Comparing enrichment of FLAG-tagged PU.1 in WEHI-279
3XFLAG-PU.1 B cell lymphoma cells with Ets-1 binding in SH12 B cell lymphoma cell
lines, there are regions where both transcription factors can be found (Figure 4.2A). The
Nfkb1 promoter is likely one of the common regions where PU.1, Spi-B, and Ets-1 can
each bind, despite the large number of unique sites bound by Ets-1 (Figure 4.2B). It is
currently unclear which other proteins are recruited by PU.1, Spi-B, and Spi-C to the
promoter to initiate or repress Nfkb1 transcription. Since PU.1 and Spi-B have been
reported to interact with IRF4 (Care et al, 2014; Escalante et al, 2002), it is possible that
PU.1 or Spi-B recruits IRF4 to regulate Nkfb1 transcription. Based on publicly available
ChIP-seq data from splenic B cells, there is a high degree of similarity in the binding
patterns seen at Nfkb1 between PU.1 and IRF4 in naïve splenic B cells (Figure 4.2C).
Moreover, there are multiple overlapping sites of transcription factor binding across the
mouse genome, when comparing ChIP-seq peaks between PU.1, Spi-B, and IRF-4 B cell
datasets (Figure 4.2D). Therefore, it is conceivable that Nfkb1 transcription can be
regulated through recruiting interacting transcription factors and related ETS
transcription factors in B cells.
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Enrichment of PU.1 and Spi-B binding did not occur most highly at the promoter
of Nkfb1. Several intronic regions of Nfkb1 contained even larger PU.1 and Spi-B
enrichment sites, suggesting that PU.1 or Spi-B may have higher affinity at enhancer
regulatory elements within the gene body. Preliminary luciferase experiments suggested
that the PU.1/Spi-B binding region in intron 6-7 of Nfkb1 was not acting as an enhancer.
Therefore, it is unclear whether the ETS binding site within the intron 6-7 of Nkfb1 is
essential for maximal expression. Analysis using luciferase constructs containing both
non-mutated and mutated forms of the intron and promoter could determine the
importance of the ETS binding site within the Nkfb1 intron. Although the intron region
may not be an enhancer, it is possible that the site is important for regulating Nfkb1
expression. PU.1 and Spi-B could be binding to the region with other transcription factors
to recruit proper chromatin remodeling complexes, or could be acting on proximal genes.
Interestingly, IκB-γ inhibits DNA binding activity of p50 (Bell et al, 1996) and is
encoded within the Nfkb1 gene (Heron et al, 1995). Therefore, PU.1 and Spi-B could also
be regulating IκB-γ expression for the purpose of a feedback-loop mechanism for
regulating NF-κB activity.
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Figure 4.2. Potential regulation of the Nfkb1 gene by other ETS and ETS-interacting
transcription factors.
(A) UCSC genome browser depiction of ChIP-seq data from WEHI-279 3XFLAG-PU.1
cells and SH12 cells showing PU.1 and Ets-1 binding at the Nfkb1 gene respectively. (B)
Venn diagram for regions of significant ChIP binding between PU.1, Spi-B, and Ets-1
from WEHI-279 3XFLAG-PU.1, WEHI-279 3XFLAG-Spi-B, and SH12 lymphoma cell
lines respectively. (C) UCSC genome browser depiction of ChIP-seq data from naïve B
cells showing PU.1 and IRF4 binding at the Nfkb1 gene respectively. (D) Venn diagram
for regions of significant ChIP binding between PU.1, Spi-B, and Ets-1 from WEHI-279
3XFLAG-PU.1, WEHI-279 3XFLAG-Spi-B, and naïve splenic B cells respectively.
Overlapping binding regions in B and D were determined by subtraction of intervals.
ChIP-seq data on Ets-1 binding in SH12 cells, PU.1 binding in naïve B cells, and IRF4
binding in naïve B cells is listed as GSM1003774, GSM537989, and GSM978747 in
GEO.
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4.2 Regulation of other NF-κB family members by PU.1, Spi-B,
and Spi-C
It has been previously reported that PU.1 and Spi-B are involved in the
transcriptional regulation of Rel, and it is required to maintain survival in B cells and
allow proper development (Hu et al, 2001). Therefore, it is predicted that PU.1, Spi-B,
and Spi-C are involved in regulating the transcription of other NF-κB family members
aside from Nfkb1 and Rel. Re-analysis of the ChIP-seq data in WEHI-279 3XFLAG-PU.1
and WEHI-279 3XFLAG-Spi-B cell lines confirmed that PU.1 and Spi-B bound proximal
to the TSS of Nfkb2, Rela, Relb, and Rel (Figure 2.11). Therefore, PU.1 and Spi-B may
be involved with the transcriptional regulation of those genes in B cells. It is
hypothesized that Spi-C would inhibit transcriptional activation of Rel, similar to its
effect on Nfkb1 transcription.
Constitutive NF-κB activation is commonly seen in lymphomas (Davis et al,
2001; Jost & Ruland, 2007). Since WEHI-279 B cells do not express Spi-C (DeKoter et
al, 2010), down regulation of Spi-C may be one method for tumor cells maintaining high
levels of NF-κB expression. To test if Spi-C inhibits Rel transcription, studies could be
performed by transfecting Rel promoter-containing luciferase constructs into WEHI-279
cell overexpressing Spi-B or Spi-C cells to determine Rel activation. Although PU.1 and
Spi-B bind near the promoters for the NF-κB genes in WEHI-279 B cells, their
importance in transcriptional regulation would need to be validated using expression
constructs containing mutated ETS binding sites. Moreover, the transcriptional regulation
of the different NF-κB members is stage specific, since different NF-κB members are
predominantly activated depending on the cell type (Liou et al, 1994). ChIP-seq analysis
could be performed using different types of B cell subsets to compare the differences in
binding enrichment at various cell stages.
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4.3 Spi-C as a repressor of PU.1 and Spi-B activity
Interactions between IRF-4 and PU.1 or Spi-B are important for regulating
promoters and enhancers for genes involved in B cell function (Pongubala & Atchison,
1997; Rao et al, 1999). Spi-C was proposed as a negative control mediator due to its
inability to interact with IRF-4 in vitro at the λB enhancer (Carlsson et al, 2003).
Subsequent gain-of-function studies suggested that Spi-C functions as a negative
regulator of transcription by opposing PU.1 activity. Overexpression of Spi-C in cultured
pro-B cells resulted in decreased FcγRIIb expression and opposed transcription of the
Fcgr2b gene mediated by PU.1 (Schweitzer et al, 2006). Furthermore, mice
overexpressing Spi-C under control of the IgH intronic enhancer (Eµ-Spi-C) contained
pre-B cells and FO B cells with reduced transcript levels of BLNK, Btk, and B220
compared to WT B cells (Zhu et al, 2008). Eµ-Spi-C B cells also proliferated poorly in
response to anti-IgM or anti-CD40 (Zhu et al, 2008). Therefore, it was suggested that
Spi-C impairs B cell function by affecting genes associated with BCR signaling.
The generation of a Spi-C deficient mouse (Spic-/-) has allowed for loss-offunction analysis for Spi-C. However, Spic-/- mice were initially reported to have no
abnormalities in B cell development (Kohyama et al, 2009). It is possible that B cells
from Spic-/- mice could have functional differences, such as increased proliferation to
TLR ligands or BCR signaling. By using Spib-/-Spic+/- mice, it was demonstrated for the
first time that reduced Spi-C expression can affect B cell proliferation and development.
Furthermore, Spi-C expression may be normally repressed in B cells. For example, when
the transcription factors Bach1 and Bach2 are deleted in mice, Spi-C is upregulated in B
cells and results in altered gene expression patterns (Itoh-Nakadai et al, 2014). The
authors concluded that expression levels of Spi-C may determine the responsiveness of B
cells, and may be required for the differentiation and function of mature B cells (ItohNakadai et al, 2014).
Overexpression of Spi-C in Spib-/-Spic+/- B cells reversed the phenotype
comparable to Spib-/-. LPS-mediated proliferation in Eµ-Spi-C Spib-/-Spic+/- mice was
impaired compared to Spib-/-Spic+/-, and there was also a significant reduction in total,
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MZ, and FO B cells in mice overexpressing Spi-C. Therefore, the data suggests that
relatively low levels of Spi-C expression are required for proper development and
function in B cells. In previous studies, Eµ-Spi-C mice were crossed to PUB mice (EµSpi-C PUB) in order to determine if Spi-C could rescue the PUB phenotype. Although
the Eµ-Spi-C PUB mice had restored frequencies of FO B cells based on CD23
expression, it remains unclear whether B cell function is restored in these mice. During
the start of the cumulative studies described in this thesis, some experiments were
performed on Eµ-Spi-C PUB mice as well. Proliferation studies were performed using
WT, PUB, and Eµ-Spi-C PUB B cells. In preliminary studies, it was found that Eµ-Spi-C
PUB B cells proliferated more poorly than PUB B cells in response to various TLR
ligands (Figure 4.3A-B). Furthermore, transcript expression levels of genes in the TLR
signaling pathway, with the exception of Myd88 and Irak4, were further reduced in EµSpi-C PUB MZ B cells compared to PUB MZ B cells (Figure 4.3). At the time, it was
unclear how overexpression of Spi-C was affecting the PUB phenotype, so those
experiments were excluded from the manuscript described in Chapter 2. However, since
there is now additional evidence demonstrating Spi-C’s involvement at being a repressor
in B cells, these studies now coincide with this idea. Therefore, the data suggests that
overexpression of Spi-C impairs the ability of B cells to function properly in response to
TLR ligands, likely due to repression of genes within the TLR signaling pathway.
Future experiments demonstrating competition between PU.1/Spi-B and Spi-C for
ETS binding sites would further elucidate the role of Spi-C in gene repression. ChIP
could be performed in Eµ-Spi-C B cells and WT B cells using anti-PU.1antibody, and
then PU.1 binding enrichment could be determined at the Nfkb1 promoter by using
qPCR. By comparing PU.1 enrichment in cells overexpressing Spi-C to those with
normal Spi-C levels, it would be possible to demonstrate decreased PU.1 enrichment in
Spi-C overexpressing cells. The same experiment would be performed with Spi-B, but
there is currently no commercially available anti-mouse Spi-B antibody for effective
ChIP applications. ChIP-seq has not been performed for Spi-B or Spi-C enrichment in
naïve B cells. In Chapter 3, a Spi-C antibody was used for ChIP in WEHI-279 3XFLAGSpi-C cells; however, the affinity of the anti-Spi-C antibody was weaker than anti-FLAG.
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ChIP-seq analysis performed on splenic B cells using anti-Spi-C antibody would help in
determining potential direct targets of Spi-C in primary B cells.

4.4 Spi-C as a transcriptional activator
Few target genes have been demonstrated to be directly activated by Spi-C. In B
cells, Spi-C has been reported to directly activate Fcer2a, which encodes for the IgE low
affinity Fc receptor (DeKoter et al, 2010), Furthermore, pro-B cells ectopically
expressing Spi-C have demonstrated direct binding of Spi-C to the IgH intronic enhancer
to initiate transcription of the Ig heavy chain (Schweitzer et al, 2006). In macrophages,
Spi-C was reported to directly regulate Vcam1 expression, which encodes for the cell
adhesion molecule vascular cell adhesion molecule 1 (VCAM-1) (Kohyama et al, 2009).
Another potential target gene of Spi-C may be Grap2, a SH2 and SH3 domain-containing
adaptor protein, shown previously to require PU.1 and Spi-B in B cells (Garrett-Sinha et
al, 2005). Interestingly, Eµ-Spi-C mice expressed elevated levels of Grap2 in FO B cells
and pre-B cells (Zhu et al, 2008), suggesting that Spi-C could directly activate Grap2
transcription. Myd88 may be a gene activated by Spi-C, since Eµ-Spi-C PUB MZ B cells
express elevated transcript levels of Myd88 compared to PUB MZ B cells (Figure 4.3C).
However, further analysis would need to be done to validate this hypothesis. The list of
target Spi-C genes could be vastly expanded by performing RNA-seq analyses. RNA
from sorted B cell subsets from Spib-/-Spic+/- and Spib-/- mice would be sequenced,
aligned, and compared for differences in splicing, promoter use, and transcript
abundance. Transcript levels of genes decreased in Spib-/-Spic+/- compared to Spib-/would suggest that Spi-C is involved in its activation. Alternatively, forced Spi-C
expression could be conducted in the pro-B cell line 38B9 using a MIG-Spi-C retrovirus.
RNA-seq analysis could be performed on Spi-C overexpressing 38B9 cells and compared
to control cells to determine target genes of interest.
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Figure 4.3. Spi-C overexpression in PUB B cells results in further impairment in TLRmediated proliferation and altered gene profiles.
(A) B cells from Eµ-Spi-C PUB mice respond more poorly than PUB B cells stimulated
with different concentrations of CL097 (TLR7 agonist). (B) B cells from Eµ-Spi-C PUB
mice responded more poorly than PUB B cells stimulated with indicated TLR9, TLR6/2,
TLR4, and TLR2/1 ligands. Data shows the mean ± SD for triplicate wells for A-B, and
is a representative of two independent experiments. ***p<0.001. (C) Altered transcript
levels of genes related to TLR signaling. RT-qPCR was performed using cDNA isolated
from WT, PUB, and Eµ-Spi-C PUB MZ B cells. Expression levels shown are relative to
WT levels.
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4.5 Intrinsic vs extrinsic effects of PU.1, Spi-B, and Spi-C –
potential uses of adoptive transfer models
A caveat to germline knockout models of mice is that the deletion affects all cells,
leading to both direct and indirect effects of gene loss in the target tissue. Therefore, a
developmental or function phenotype could be due to defects in multiple cell types. For
example, Spi-B is expressed in pDCs, and is critical for its development and function
(Sasaki et al, 2012). Upon TLR7 or TLR9 ligand stimulation, Spib-/- pDCs have impaired
cytokine production (Sasaki et al, 2012). Therefore, it is possible that the limited
production of cytokines by pDCs in Spib-/- mice could alter development and function of
B cells. The possibility of extrinsic effects caused by Spi-C on B cells was partially
addressed by crossing the Eµ-Spi-C mice to Spib-/-Spic+/- mice. Since overexpression of
Spi-C occurs through the B cell-specific IgH intronic enhancer (Zhu et al, 2008), the
developmental and proliferation impairment in c mice must have been a cell- intrinsic
effect of Spi-C in B cells. However, there could still be cell-extrinsic effects on the B cell
lineage as a result of whole-body loss of Spi-B. To fully address these limitations without
generating a conditional knockout mouse, adoptive transfer models could be used. Fetal
liver cells from WT, PUB, Spib-/- and Spib-/-Spic+/- mice would be isolated and injected
into irradiated B cell deficient (µMT) mice, and cells would be allowed to reconstitute for
four weeks. Flow cytometry analysis could be performed on the blood, spleen, and bone
marrow to assess B cell development. Defects detected upon knockout cell reconstitution
would suggest intrinsic effects caused by genes deleted in transferred cells.

4.6 Generation of a conditional knockout model for Spi-C
While conditional knockout models exist for PU.1 in B cells (Polli et al, 2005;
Sokalski et al, 2011), similar models have not been generated for Spi-C. Generating a B
cell conditional knockout mouse for Spi-C using the Cre/LoxP system would be highly
beneficial. The conditional knockout would bypass the issues of embryonic lethality and
confounding factors caused by all cells lacking Spi-C. Germline Spic knockout mice
appear to cause at least partial embryonic lethality (Kohyama et al, 2009), and this
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observation becomes more apparent when crossing the Spic null allele to mice which are
germline Spib knockout.
In order to utilize the Cre/LoxP system, the Spic gene would need to be flanked
by LoxP sites for targeted deletion. One strategy would be to target exon 6 of the Spic
gene which contains the ETS DNA binding domain, a similar approach performed for
Spi1 gene (Polli et al, 2005). The targeting vector would contain LoxP sites flanking
(floxed) the coding region of exon 6, and a reporter cassette containing IRES-GFP and a
selection marker neomycin (neo) flanked by Frt sites prior to the 3’ UTR (Figure 4.4).
Once the vector has been homologously recombined into mouse embryonic stem cells,
clones could be selected by GFP expression and neomycin resistance. Chimeric mice
generated would contain GFP in the Spic locus (Spi-CGFP), which would allow for
measuring Spi-C levels by flow cytometry. In order to remove the GFP reporter cassette,
chimeric mice generated could be crossed to mice expressing flp recombinanse to
generate Spi-Clox mice. A B cell-specific Cre mouse which could be used is the Mb1-Cre
mouse, where Cre is expressed under the control of the Ig-α subunit of the BCR. The
benefit of using the Mb1-Cre mouse rather than the CD19-Cre mouse is that the
efficiency of targeted deletion is greater (Hobeika et al, 2006). Crossing Spi-Clox mice to
Mb1-Cre mice would delete the floxed exon 6 of Spi-C to generate Spi-CΔ mice, which
lack Spi-C expression in the B cell lineage only. In addition, mice with total Spi-C
deletion in all cells could be generated as controls, by crossing Spi-Clox mice to deleterCre mice (Schwenk et al, 1995).
It is unclear at which stages of B cell development levels of Spi-C are required for
proper function or development. Spi-C levels have previously been reported to be lowest
at fractions A-C in the bone marrow, and highest in immature B cells in the spleen (Zhu
et al, 2008). The use of Spi-CGFP mice would be useful in comparing the levels of Spi-C
between different stages of B cell development through the convenience of flow
cytometry, since GFP expression would correlate with the levels of Spi-C. Since Spi-C is
involved with blastocyst development (Kageyama et al, 2006), Spi-CGFP mice would be a
useful system to determine Spi-C expression during embryogenesis. Aside from
analyzing development in the bone marrow and spleen, B cells from other tissues such as
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the peritoneal cavity and lymph nodes could be analyzed. It is hypothesized that Spi-C
has a role in B-1 cell function. In one study, microarray analysis was performed on
splenic and peritoneal B-1 cells to compare gene expression profiles, and it was found
that splenic B-1a cells expressed higher Spi-C transcript expression levels compared to
peritoneal B-1a, B-1b, or splenic B2 cells (Kretschmer et al, 2003). Interestingly,
CD19+CD5+ B-1a cells from the peritoneal cavity of Spib-/-Spic+/- mice express elevated
levels of CD19 compared to WT B-1a cells (Figure 3.2C), suggesting that Cd19
expression may be a repressor target gene of Spi-C. Therefore, levels of Spi-C expression
may be involved with proper B-1a cell function.
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Figure 4.4. Conditional deletion of Spi-C.
Spi-C targeting construct containing exon 6 of Spic flanked by LoxP sites (►). The
reporter cassette contains an internal ribosome entry site (IRES), green fluorescent
protein (GFP) and a neomycin (Neo) selection marker flanked by Frt sites (●). GFP and
Neo are driven by the phosphoglycerate kinase (PGK) promoter. The targeting construct
is introduced into the Spic locus by homologous recombination to generate Spi-CGFP
mice. The reporter cassette is removed by crossing Spi-CGFP mice to mice expressing flp
recombinase, generating Spi-Clox mice. Exon 6 of Spic is deleted by crossing Spi-Clox
mice with mice expressing Cre recombinase, creating Spi-CΔ mice.
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4.7 Existing conditional knockout models for PU.1 and Spi-B
Our laboratory has generated mice with deleted Spi1 under the control of the B
cell-specific Cd19 locus on a Spib-/- background (CD19+/creSpi1lox/loxSpib-/-) (Sokalski et
al, 2011). These mice have few CD19+B220+ B cells within the spleen. Moreover, these
mice develop B cell acute lymphoblastic leukemia with 100% incidence by 21 weeks of
age (Sokalski et al, 2011). Therefore, B cell deficiency in these mice combined with
leukemia precludes the use of this model to study mature B cell function. Another
conditional knockout model which was generated by our lab utilizes the Mb1 gene to
drive

cre-recombinase

to

delete

floxed

Spi1

on

a

Spib-/-

background

(Mb1+/creSpi1lox/loxSpib-/-). Mb1 encodes for CD79a, a membrane glycoprotein which is
part of the BCR. The Mb1 driven Spi1 deletion resulted in an elevated fraction C cell
population and a developmental block at the fraction D stage in the bone marrow (Figure
4.5A-C). Spleens of Mb1+/creSpi1lox/loxSpib-/- mice contained no mature B220+IgM+ B cells
in the spleen (Figure 4.5D), but contained an abnormal immature B220+CD93+ B cell
population which was negative for both CD21 and IgM (Figure 4.5E-F). The
B220+CD93-CD21-IgM- B cell population in spleens of Mb1+/creSpi1lox/loxSpib-/- mice is
similar to the leukemic population previously described in CD19+/creSpi1lox/loxSpib-/(Sokalski et al, 2011). Therefore, Mb1+/creSpi1lox/loxSpib-/- are likely prone to developing
leukemia with age, as observed in CD19+/creSpi1lox/loxSpib-/- mice (Sokalski et al, 2011).
An advantage of the Mb1+/creSpi1lox/loxSpib-/- mouse is that the developmental block is
more defined than in the CD19 condition knockout. It would be possible to determine the
effects of Spi-C at these early stages of development, since transcript levels of Spi-C rise
during the transition from CD43+ (Fraction A-C) to CD43- (Fraction D-F) stage (Zhu et
al, 2008). Expression of Spi-C could have a role in the leukemia mouse models. Spi-C
expression could be either increased or decreased by crossing leukemia prone mice to
Eµ-Spi-C or Spib-/-Spic+/- mice respectively. Since reduction of Spi-C increased
proliferation in Spib-/- mice, it is conceivable that decreased Spi-C levels in
CD19+/creSpi1lox/loxSpib-/- mice would exacerbate the disease. In contrast, overexpression
of Spi-C could alleviate the disease, since overexpression of Spi-C in Eµ-Spi-C PUB
mice decreases B cell proliferation.
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Figure 4.5. Impaired B cell development in mice deficient in PU.1 and Spi-B.
(A) Bone marrow cells gated on B220 and CD43 for identifying “Hardy” B cell fractions
in bone marrow. (B) Increased Fraction C population (BP-1+CD24+B220+CD43+) in
Mb1+/creSpi1lox/loxSpib-/- bone marrow. (C) Developmental block at Fraction D
(B220+IgM-CD43-) in Mb1+/creSpi1lox/loxSpib-/- bone marrow. (D) Absence of mature
B220+IgM+ cells in the spleen of Mb1+/creSpi1lox/loxSpib-/- mice. (E) An abnormal CD93hi
immature B cell population exists in the Mb1+/creSpi1lox/loxSpib-/- spleen. (F) The immature
B cells in Mb1+/creSpi1lox/loxSpib-/- spleen are primarily CD21 and IgM negative. Analysis
for A-F was performed by flow cytometry and are a representative of 3 independent
experiments.
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4.8 In Vivo Studies
Proliferation studies performed in this thesis were ex vivo models. Primary B cells
were isolated from the spleens of mice and cultured in media with TLR-ligands. The
measured response in an in vitro culture system is a simplification a cell’s response.
Since the B cells are no longer in their native environment, they are not in contact with
other cell types within the confines of the structural organ, or with cytokines produced by
other cells which could influence the response in B cells. Therefore, in vivo proliferation
studies could be performed to further enhance the current results of this thesis. A
common method to measure proliferation in vivo is based on 5-Bromo-2’-Deoxyuridine
(BrdU) incorporation and detection by flow cytometry (Carayon & Bord, 1992).
Proliferation analysis by BrdU incorporation would allow multiple B cell subsets to be
simultaneously measured between different strains of mice, following inoculation with
specific antigens such as DNP-KLH or DNP-LPS.
Unfortunately for the described studies in chapter 2 and chapter 3, in vivo
response studies could not be effectively performed since the mice were housed in a
conventional facility. For future studies, the mice would need to be re-derived in a
specific pathogen free animal facility for proper in vivo studies. WT, Spib-/-, and Spib-/Spic+/- mice immunized for DNP-KLH or DNP-LPS would be used to differentiate
differences in TD and TI immune responses respectively. Flow cytometry and
immunohistochemistry analysis could be performed on the spleen and lymph nodes to
assess differences in germinal center formation. Anti-DNP-KLH or anti-DNP-LPS
ELISAs could determine differences in antibody production using serum collected from
mice. Immunization studies performed in Spib-/-Spic+/- mice would determine whether
Spi-C has an effect on germinal center formation, or antibody production.
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4.9 Significance of these studies
ETS transcription factors are likely involved with transcriptionally regulating
BCR and TLR signaling genes. Since TLR and BCR signaling are both required for
optimal antibody responses, PU.1, Spi-B, and Spi-C can potentially regulate antibody
formation. Studying the regulatory interactions between TLR and BCR signaling will
allow improved predictions of B cell responses during immunization approaches.
Determining the genes essential for antibody formation could provide therapeutic
interventions for immunodeficiencies, or improve development of effective vaccines.
Determining how B cells respond to different antigens can lead to novel developments of
vaccine adjuvants or synthetic vaccines designed to activate appropriate amounts of TLR
and BCR signaling.
Proper levels of Spi-C likely need to be regulated during B cell development. I
hypothesize that reduced Spi-C levels can alter B cell function during development
through the transitional B cell stages. Peripheral tolerance of B cells may be regulated by
Spi-C through BCR signaling genes. Spi-C may negatively regulate genes involved in
BCR signaling, which can affect the differentiation of T1 to T2 B cells. The
developmental block at the T2 stage in Spib-/- mice could result from a combination of
Spi-B failing to activate BCR signaling genes, and Spi-C inhibiting those same genes.
Reduced Spi-C expression could potentially alleviate defects in antibody production
observed in Spib-/- mice. It is possible that as Spic-/- mice age, these mice could be prone
to developing autoimmune or leukemic diseases due to an accumulation of T1 B cells and
a failure of peripheral tolerance.

4.10 Concluding Remarks
The long-term goal of this research is to understand how ETS transcription factors
regulate B cell development and control immune responses to TI and TD antigens. The
studies presented in this thesis demonstrate the importance of the ETS transcription
factors PU.1, Spi-B, and Spi-C in directly regulating Nfkb1 transcription, which is highly
involved in humoral immune responses and B cell development. The network of
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transcription factors regulating other transcription factors gives appreciable insight to the
complexity of gene regulation.
Studies on Spi-C are still at their infancy. Most published studies have attributed
Spi-C towards a function in macrophages, but its expression is not limited to one
particular cell type. By determining that Spi-C has a negative regulatory role in B cell
development and function, our study provides new insight on how PU.1 and Spi-B target
genes are regulated. Nfkb1 is one of many genes likely regulated in opposing fashion
between PU.1/Spi-B and Spi-C. Genes activated by PU.1 and Spi-B during antibody
responses, drug treatments, and cancer growth could all be influenced by Spi-C’s
inhibition. Hopefully, the advancement of this work yields new questions and answers in
the fields of transcriptional regulation and B cell biology.
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